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Abstract 
 
Acquired or inherited genetic alterations either alone or in combination with epigenetic alterations are associated 
with prostate carcinogenesis and its progression toward advance metastatic or castration-resistant disease. A 
major objective of translational cancer research in post-genome era is to discover the repertoire of genetic and 
epigenetic  variations  associated  with  prostate  cancer.  Genome-wide  association  studies  have  been  at  least 
partially successful in identifying potential germline polymorphisms and allelic imbalances such as microsatellite 
instability and loss of heterozygosity associated with prostate cancer susceptibility. Epigenetic mechanisms such 
as DNA hyper- or hypomethylation and histone modifications are reversible genetic alterations which allow stable 
inheritance of cellular phenotypes without any changes in the DNA sequence or quantity. Epigenetic modifica-
tions can potentially be used for the molecular classification, detection, and risk assessment in prostate cancer. 
Chemical inhibitors of DNA methyltransferases and histone deacetylases have been used in different clinical 
trials and hold promise as novel chemotherapeutics to be effective alone or in combination with other therapeutic 
interventions in prostate cancer. 
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Introduction 
 
Prostate cancer (PCa) is the most frequently diagnosed 
non-skin tumor and the second leading cause of can-
cer-related  deaths  in  the  male  population  in  most 
Western countries.
1 With the increasing usage of pros-
tate-specific  antigen  (PSA)  testing,  there  is  an  in-
creased tendency to diagnose PCa in developing coun-
tries.
1,2 Race, family history and age are the unequivo-
cally accepted risk factors for PCa. It is well estab-
lished that  PCa  does  not affect  racial/ethnic  popula-
tions similarly. In 2007, PCa was accountable  for 37% 
of all cancers in African-American men in the United 
States.
2 African American men have a 1.6-1.9 times 
higher incidence rate and 2-3 times greater mortality 
rate than Caucasians. These findings showed to be per-
sistent for more than two decades, before and after the 
PSA era.
3 Black men of West African ancestry from 
the Caribbean and South America share a similar inci-
dence  and  mortality  rate  when  compared  to  African 
American men. In this ethnic group, PCa presents with 
a higher tumor volume, more advanced tumor stage, a 
higher Gleason score, and a higher PSA. Overall, Afri-
can American men have a worse prognosis than their 
Caucasian  counterparts.  The  underlying  reasons  for 
such disproportionate ethnic differences in PCa prog-
nosis and mortality are unclear. In part, genuine racial 
differences  in  cancer  genetics  and  biology,  socio-
cultural differences, and/or access to health care sys-
tems are responsible but these factors do not totally 
explain the higher mortality rate in African Americans 
with PCa.  
PCa is known to be an indolent disease, but up to 
30% of the tumors progress aggressively. PCa typi-
cally  initiates  as  androgen-sensitive lesions  but fre-
quently  develops  into  androgen-insensitive  lesions 
with  progression  to  an  advanced  stage  (Figure  1). 
Androgens  and  other  steroid  hormones,  acting  via 
their receptors, regulate the development and mainte-
nance of the differentiated functions of the male re-
productive system and have been implicated in PCa 
development  and  progression.
3  Currently,  available 
methods for PCa treatment aim to inactivate the an-
drogen  receptor  (AR)  by  androgen  deprivation  or 
blockade  with  anti-androgens.  The  majority  of  the 
patients with early metastatic disease could be treated 
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with androgen-deprivation therapy which leads to a 
significant  reduction  of  androgen-responsive  cancer 
cells. Androgen-deprivation via chemical or surgical 
castration leads  an initial and  clinically  satisfactory 
treatment.  However,  the  tumor  almost  always  be-
comes hormone-refractory and more aggressive in the 
later  stages,  leading  to  a  poor  prognosis,  incurable 
disease,  and  death.
4  However,  contrary  to  localized 
PCa  which  can  be  effectively  treated  with  radical 
prostatectomy  or  other  modalities,  hormone-
refractory disease does not have effective therapeutic 
options.  Currently,  available  therapeutic  approaches 
for advanced or metastatic stages of PCa are only pal-
liative rather than curative. 
Failure of endocrine therapy and tumor progres-
sion is characterized by androgen-independent growth 
despite the presence of high levels of AR expression 
in  metastatic  disease.  The  persistent  expression  of 
PSA, as an androgen responsive gene despite maxi-
mal androgen blockade has led many researchers to 
investigate alternative signaling pathways for the AR 
activation in PCa. Although the role of androgen is 
important, it is insufficient to maintain normal pros-
tate homeostasis by itself. This process also requires 
complex interactions between peptide growth factors 
and other growth modulators that may be regulated 
either by androgens or other factors. Additionally, a 
number of neuropeptides produced locally by neuro-
endocrine  cells  can  also  stimulate  mitogenesis  and 
affect  the  biological  behavior  of  PCa  cells.
5  As  in 
many other cancers, genome-based technologies and 
approaches have demonstrated the accumulation of a 
variety of genetic defects, hypermutator phenotypes, 
and  epigenetic  processes  (e.g.,  hypermethylation  of 
tumor  suppressors,  hypomethylation  of  oncogenes, 
histone modification, genomic imprinting) that would 
eventually  create  the  gene-specific  or  genome-wide 
genetic instability in the form of microsatellite insta-
bility  (MSI),  loss  of  heterozygosity  (LOH),  allelic 
loss (AL), single nucleotide polymorphisms (SNPs), 
somatic and germline mutations, chromosomal aber-
rations (e.g., chromosomal breaks, translocaions, re-
combinations), and ETS gene fusions during the natu-
ral history of PCa (Figure 2).  
Indeed, PCa resembles proteus by having a varied 
nature, the ability to assume different forms and the 
ability  to  display  of  great  diversity  of  clinicohisto-
pathological  behaviors  which  challenge  clinicians. 
During the last decade, significant progress has been 
made in understanding the underlying biological and 
molecular  genetic  mechanisms  involved  in  prostate 
carcinogenesis  and  its  progression  toward  an  ad-
vanced or metastatic stage. It is anticipated that by 
knowing the molecular signature of a PCa patient, we 
would be able to develop reliable predictive models 
for PCa prognosis, clinical behavior of the disease, 
and response to treatment, and to provide an individ-
ualized, targeted intervention.   
 
Fig. 1: Multistep prostate cancer development and progression.  
 
Normal prostate gland aging eventually leads to benign prostatic hyperplasia (BPH) in adult males. Malignant de-
velopment of the prostate may originate from prostate intraepithelial neoplasia (PIN) which, in turn, may remain as a 
clinically or histologically dormant lesion, progresses into organ-confined or a locally invasive tumor, and finally, 
evolve into hormone-refractory or metastatic disease. Koochekpour 
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In  this review,  I  focus  on  current  knowledge  of 
genetic and epigenetic alterations in human PCa and 
discuss  their  potential  or  practical  implications  for 
PCa screening, diagnosis, and treatment. 
 
A. Genetic Alterations in Prostate Cancer 
PCa development results from the progressive ac-
cumulation of multiple genetic events. These events 
provide a hospitable soil for additional genetic altera-
tions in the tumor microenvironment. Modern genetic 
and  genome-based  technologies  have  provided  evi-
dence  for  the  presence  of  somatic  alterations  and 
germline variations which not only individualize PCa, 
but also serve as a driving force for prostate carcino-
genesis and its progression toward advance incurable 
stages. Gene expression and microarray analyses of 
somatic alterations in PCa revealed the role of certain 
tumor suppressor genes (TSGs) and oncogenes. 
Oncogenes  are  essentially  the  product  of  proto-
oncogenes  which  have  been  subjected  to  genetic 
changes such as mutations, deletions, rearrangements, 
overexpression,  or  amplifications.  Such  oncogenic-
conversions  lead  to  uncontrolled  growth  and  other 
exaggerated  phenotypes  which  are  most  commonly 
associated with malignant cells. For example, a single 
missense point mutation in the Ras gene converts it to 
a  potent  oncogene.  In  addition  to  Ras,  c-Myc,  c-
ErbB2 (Her2/Neu), and Bcl-2 oncogenes have been 
implicated in PCa (Table 1). 
Similarly, genetic aberrations such as mutations, 
deletions,  haplo-insufficiency,  and  promoter  hyper-
methylation have the ability to inactivate or divert the 
TSGs  from  their  native  role  as  tumor  suppressors. 
Several TSGs have been associated with prostate car-
cinogenesis  and  its  androgen-independent  or  hor-
mone-refractory progression. The p53 gene, known as 
the guardian of the normal genome, is the most com-
monly mutated gene in human malignancies includ-
ing PCa. The p53 gene is mutated in approximately 
10-20% of primary and up to 42% of advanced PCa.
6-8 
Among other TSGs, PTEN mutations are detected in 
up to 27% of localized and up to 60% of metastatic 
tumors.
9-11  
 
Fig. 2: Possible risk factors in prostate carcinogenesis and progression. 
Natural history of prostate cancer appears as a versatile phenomenon with numerous contributing risk and/or etio-
logical factors. These factors include age, family history, race, dietary and environmental elements, steroid hor-
mones and their receptors, and growth regulators in connection with genetic make up and epigenetic processes 
which eventually lead to genetic instability and subsequently, to the progressive disease. Prostate cancer genetic and epigenetic 
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In addition to the classically known oncogenes, the 
AR has been considered as an oncogene that is in-
volved  specifically  in  prostate  carcinogenesis  and 
PCa recurrence. Due to its special role, we describe 
its genetic alteration in more details. Functional AR is 
expressed at any stage of PCa including prostate in-
traepithelial neoplasia (PIN), primary PCa, and meta-
static PCa before and after androgen-ablation therapy. 
Androgen-dependent and androgen-independent acti-
vation of the AR have been proposed as major events 
in PCa progression. The AR gene is located on the X 
chromosome at position Xq11-12 and spans ~90 kb 
containing eight exons that code for a ~2,757 bp open 
reading frame within a 10.6-kb mRNA. The AR is a 
nuclear transcription factor and a member of the ster-
oid hormone receptor superfamily of genes. The nor-
mal  growth,  development,  and  maintenance  of  the 
prostate  are  dependent  on  androgen  acting  through 
the  AR.  Loss  of  androgen-dependence  in  PCa  re-
mains  a  key  dilemma  in  treating  this  malignancy. 
Several AR-related mechanisms have been proposed 
for metastatic or androgen-independent PCa progres-
sion including: 1) AR amplification, 2) a hypersensi-
tive AR resulting from point mutations, 3) promiscu-
ous mutant-AR protein activated by non-androgenic 
ligands  and  4)  AR-polymorphisms  changing  the  re-
sponse  to  androgen  (e.g.,  poly-CAG  repeat).  The 
functional significance of an AR mutation in PCa is 
represented in the LNCaP cell line where the AR gene 
is mutated at codon 877 (Thr to Ala).
12 Due to this 
mutation, the growth of LNCaP is stimulated in vitro 
not only by androgens, but also by non-androgenic 
steroids  (e.g.,  estrogens,  progesterone)  and  anti-
androgens. The AR is among the most mutated type 
of the steroid receptors. So far, more than 700 muta-
tions of the AR have been reported, most of which led 
to different, non-malignant clinical categories of an-
drogen-insensitivity  syndrome.
13  Overall,  AR  muta-
tions  in  Caucasian  patients  are  rarely  found  in  un-
treated  localized  PCa  (<2%),  but  are  detected  at  a 
high  frequency  in  hormone-refractory,  androgen-
ablated, and metastatic tumors.
13,14 The frequency of 
AR mutation varies greatly among different studies, 
up to 25% in AD tumors and up to 50% in some met-
astatic  hormone-refractory  tumors.
15  The  gain  of 
function mutations of the AR in PCa are detected in 
different functional domains and rarely in 5’- and 3’-
UTRs of the gene. Most of these mutations are single 
base substitutions that directly or indirectly affect the 
AR function. About 49% of the mutations are located 
in the LBD, 37% at the NTD, and 7% at DBD. Unlike 
somatic mutations, germline AR mutations are rarely 
identified. The result of several linkage studies of he-
reditary PCa have not showed a linkage to the Xq11-
q12 chromosomal region of AR indicating that the AR 
gene may not be a major PCa susceptibility gene.
16,17 
However, it does not exclude the possibility that the 
AR as a low to moderate peneterance, predisposing 
gene for PCa. The existing reports on  AR germline 
mutations in PCa are limited to Caucasian patients. 
The R726L mutation was reported in Finnish patients 
with sporadic or familial PCa.
18,19 Additional reports 
Table 1: Common somatic genetic changes in prostate cancer. 
Gene  Chr  Event  Function 
ETS genes
a  7  Fusion to AR-targeted genes 
(TMPRSS2)
c 
Transcription factors, differentiation, 
growth 
NKX3.1
f  8p21  Inactivation  Cell growth/differentiation 
c-Myc  8q  Genomic amplification  Cell growth/differentiation 
PTEN
e  10q23  Inactivation  Cell growth/metabolism 
GST-Pi
d  11  Promoter methylation  Oxidative stress response 
Rb
g  13q  LOH, mutation
h  Cell cycle regulation 
P53  17p  LOH, mutation  Cell cycle regulation, apoptosis, DNA 
damage detection 
ETS genes  21  Fusion to AR-targeted genes 
(TMPRSS2) 
Transcription factors, cell growth 
/differentiation 
AR
b  X  Mutation, 
 genomic amplification 
Cell growth/differentiation 
a ETS: ETS family of transcription factors, 
b AR, androgen receptor, 
c TMPRSS2, transmembrane protease serine 
type 2, 
d GST-Pi, glutathione S-transferase pie, 
e PTEN, phosphatase and tensin, 
f NKX3.1, NK3 homeobox 1, 
g Rb, 
retinoblastoma, 
h LOH, loss of heterozygosity. Koochekpour 
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include  two  unrelated  PCa  patients  with  G2T  and 
C214A  mutations  within  the  5’-UTR  (non-coding) 
region of the AR
20 and one final report showed the 
AR-Q798E mutation in the PCa tissue and the gDNA 
of  a  patient.
21  AR  somatic  and  germline  mutations 
have  been  recently  reported  in  African  Americans 
with sporadic or familial PCa.
22-24 While investigating 
AR sequence in the E006AA cell line derived from a 
Gleason  6  organ-confined  tumor,  we  observed  X 
chromosome duplication and AR gene amplification. 
Somatic AR mutation (599 S>G) in this cell line was 
proved to be as dominant-negative or loss-of-function 
type.
23 In addition, in author’s laboratory, a germline AR 
(A1675T:T559S)  substitution  mutation  in  the  DNA-
binding domain was discovered for the first time in three 
PCa-affected members of an African-American family 
with a history of early-onset disease.
24 
 
B. Important DNA Polymorphisms in Prostate Cancer 
In  two  randomly  selected  human  genomes,  only 
0.1% of the DNA sequence (i.e., 3 x 10
6 bases) is not 
identical. This variation is known as a polymorphism. 
The simplest form of this variation is the substitution 
of one single nucleotide for another, termed single-
nucleotide polymorphism (SNP). SNPs are the most 
common  type  of  polymorphisms  and  occur  with  a 
frequency of 1 in 250 base pairs in the entire genome 
including the promoter region, exonic sequences, in-
tronic  sequences,  and  other  non-coding  sequences. 
These simple DNA sequence changes may or may not 
change the encoded amino acids. SNPs may influence 
promoter  activity,  DNA  and  pre-mRNA  confor-
mation, mRNA stability, and play a direct or indirect 
role  in  phenotypic  expression.  Comparative  studies 
on identical twins, fraternal twins, and siblings sug-
gest that genetic variations in the form of SNPs is one 
of the factors associated with a susceptibility to many 
common  benign  and  malignant  diseases  such  as 
asthma, diabetes, cancer, hypertension, migraine, and 
human traits such as tallness, curly hair, and individ-
uality
25-28 (Table 2). In addition, several investigators 
reported important polymorphic variants of androgen-
regulatory genes in PCa (Table 3). 
A relatively long fragment of DNA with approxi-
mately 100 kilobases and a distinctive set of SNPs for 
any given location of a chromosome is called a haplo-
type. Haplotype diversity among individuals may be 
generated by new SNP alleles originating secondary 
to mutations at various loci.
29 The technological de-
velopment of SNP microarrays has enabled simulta-
neous  detection  of  a  significantly  large  number  of 
polymorphic  loci.  SNP  genotyping  methods  allow 
investigators to detect copy number changes and sig-
nal intensity variations together with the changes in 
allelic  composition,  loss  of  heterozygosity  (LOH), 
and  linkage  analysis  of  cancer  susceptibility  loci. 
While the  high  density  resolution  of  SNP arrays  is 
clearly  an  advantage,  like  other  DNA  array-based 
methods, SNP microarray analyses have several limi-
tations  including  the  inability  to  detect  balanced 
chromosomal  translocations,  inversions,  and  whole-
genome  ploidy  changes.  Several  investigators  have 
provided evidence in support of the association be-
tween SNPs and sporadic, hereditary, or familial PCa. 
Other studies have been carried out to predict PCa 
risk with genome-wide association (GWA) SNPs. The 
overall magnitude of effect for individual GWA SNP 
is small and might only account for 15% risk; for fa-
Table 2: SNPs with strong association with prostate cancer. 
Chr
b  SNP
 a Reference #  Alleles (-
/+)
d 
OR
c  Function  Refs 
11q13  7931342  T/G  1.21  Intergenic sequence  25 
26 
19q13  2735839  A/G  1.37  Androgenic effect  27 
26 
7q21  6465657  T/C  1.19  Membrane trafficking  26 
10q11  10993994  C/T  1.38  Tumor suppression  25 
26 
17q12  4430796  G/A  1.22  Tumor suppression /epithelial differen-
tiation 
27 
25, 26 
Xp11  5945619  T/C  1.29  Apoptosis, DNA repair, stress re-
sponse 
28 
26 
10q26  4962416  T/C  1.18  Antiapoptic properties  25 
6q25  934554  C/T  1.21  Drug detoxification properties  26 
17q24  1859962  T/G  1.2  Intergenic sequence  27 
26 
3p12  2660753  C/T  1.3  Intergenic sequence  26 
a SNP, single nucleotide polymorphism; 
b Chr, chromosome; 
c OR, odds ratio related to having an additional copy 
of the risk allele; 
d Alleles (-/+), the right allele is associated with increased PCa risk. 
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milial PCa; therefore, due to their low value for pre-
dicting familial PCa risk, it is unlikely that they may 
account for high percentage of sporadic PCa in the 
general population. However, a combination of indi-
vidual SNPs which are independently associated with 
PCa can significantly (2 to 4-folds) increase the risk 
of PCa among the carriers of risk-alleles.
30-32  
 
Polymorphic CAG/GGC Repeats of AR Gene 
Androgens  are  native  ligands  for  the  AR.  The 
most variable region of the AR is the N-terminal do-
main  (exon  1)  with  555  amino  acid  residues.  This 
domain has several regions of highly repetitive DNA 
sequences.  Two of the most highly recognized AR 
gene polymorphisms are the (CAG)n and (GGC/N)n 
repeats. The most important is a CAG triplet that be-
gins at codon 58 with an average of 22 repeats. In 
vitro studies have demonstrated an inverse relation-
ship between the length of both repeats and the AR 
activity level.
33 With respect to CAG repeats, studies 
have suggested that 27 alleles ranging from 5 to 31 
repeats could be detected in various populations. Ear-
lier studies indicated that short CAG repeats (≤ 22) 
are more prevalent in African American males (75% 
with short alleles; median length, 18), less frequent in 
European-Americans (62% with short alleles; median 
length, 21), and least common in Asians-Americans 
(49% with short repeat alleles; median length, 22);
34 
thus, an AR with shorter CAG repeat lengths is more 
prevalent in racial groups with higher PCa risk. Short 
CAG repeat lengths also correlate with early onset of 
PCa suggesting that early tumorigenesis is dependent 
on a more active AR.
11,12 The biological significance of 
polyglycine (GGC/N) repeat in the exon 1 is less clear; 
hence, some studies have proposed that the size of the 
glycine repeats might increase the PCa risk.
35-37 Chang 
et al. suggested that AR alleles with ≤ 16 GGC repeats 
are associated with PCa risk.  However, it was  most 
recently revealed that there is no significant association 
between CAG/GGC polymorphisms and PCa risk in 
African Americans or Caucasian Americans.
36-38 
 
Cell-Cycle Related Genes 
SNPs of cell cycle regulating genes have been in-
vestigated in several PCa association studies. Kibel et 
al  investigated  nine  SNPs  of  TP53,  CCND1, 
CDKN1A, CDKN1B, CDKN2A, and MDM2 and dis-
covered  that  the  t  allele  of  MDM2  was  the  most 
Table 3: Important polymorphisms of androgen-regulatory genes. 
Gene  Polymorphism  Normal function  Effect of polymorphism 
AR
d  CAG or GGC  Prostate growth/ 
Differentiation 
Structural change in AR  
  726(R>L)    Changes in transcriptional activity of AR 
  1733(g>a)    Increased PCa risk 
  748 (a>t)    Reduced AR stability 
CYP17
e  27(t>c)  
(-34) 5’-UTR 
Steroid metabolism  By generating one more SP1-binding motif 
increases transcription rate 
CYP1B1
f  355(g>t)  Testosterone hydroxylation  Amino acid substitution 
  100 (c>t)    Unknown 
  263(g>a)    Unknown 
  13(c>t)    Unknown 
  142(c>g)    Amino acid substitution 
CYP3A4
g  CYP3A4
g1B 
[392(a>g)] 
Oxidative metabolism of testos-
terone 
Unknown / SNP in the promoter 
CYP3A5
h  CYP3A5
h3  Metabolic detoxification 
or clearance 
Reduction of enzymatic activity/defect in 
splicing 
CYP3A43  CYP3A43*3 
31867(c>g) 
Testosterone metabolism  Amino acid substitution 
SRD5A2  TA (n) repeats 
at 3’-UTR 
5α-reductase/converts testos-
terone to DHT 
Unknown 
a DHT, dihydrotestosterone, 
b SNP, single nucleotide polymorphism, 
c UTR, untranslated region of gene, 
dAR, an-
drogen receptor, 
e CYP17, cytochrome P450C17α, 
f CYP1B1, cytochrome P4501B1, 
g CYP3A4, cytochrome 
P4503A4, 
h CYP3A5, cytochrome P4503A4 Koochekpour 
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promising allele associated with PCa.
39 The presence 
of  at  least  one  copy  of  the  t  allele  of  MDM2 
tSNP309g was associated with an increased risk of 
advanced PCa (odds ratio [OR] 2.26, 95% CI 1.15–
4.46).  This  association  was  particularly  strong  in 
hormone-refractory  PCa  (OR  2.28,  95%  CI  1.01–
5.12)  and  a  younger  age of  diagnosis. The  MDM2 
tSNP309g is located in the promoter region and in-
creases  the  affinity  for  the  transcription  factor  Sp1 
which increases MDM2 expression levels. In another 
study analyzing six SNPs in p53, p21, MDM2, PTEN, 
GNAS1, and bcl2 genes, there was a significant in-
crease in the frequency of the GNAS1 C/C genotype 
in PCa patients compared with control subjects.
40 
 
Cell-Adhesion Regulatory Genes 
Among  the  cell  adhesion  molecules,  the  E-
cadherin is a highly polymorphic gene. Its aberrant 
expression  is  associated  with  malignant  prostate 
transformation, metastatic potential of primary PCa, 
and poor prognosis.
41-43 The -160C/A polymorphism 
of E-cadherin promoter has been intensively studied 
in carcinomas. The transcription activity of the A al-
lele is 68% less than the C allele.
44 Verhage et al. 
have  demonstrated  that  the  A  allele  frequency  was 
significantly higher in PCa patients than in the control 
subjects.
45 The A-allele carriers had a relative risk of 
4.6 (2.3–9.3) for sporadic and 2.2 (0.9–5.2) for hered-
itary PCa. 
The intercellular adhesion molecules (ICAMs) are 
a group of proteins involved in cell adhesion and sig-
naling associated with several human cancers, includ-
ing endocrine-regulated breast and PCa.
7,8,46 Expres-
sion alterations in these adhesion molecules may lead 
to  the  destruction  of  tissue  architecture  and  distant 
metastasis.
48,49 Chen et al. investigated the association 
between  ICAM  genes  polymorphisms  and  risk  of 
PCa.  They  identified  that  two  SNPs  (−9  A/C  and 
K469E) in the ICAM-1 gene that were associated with 
PCa risk in men who had a positive family history of 
PCa. In addition, there was an increased risk of dis-
ease for those with the CC genotype (-9 A/C variant) 
of the ICAM-1 gene and those with at least one G al-
lele of non-synonymous K469E variant. Finally, they 
found a significant association in PCa for a common 
haplotype  within  the  ICAM  gene  cluster  containing 
the -9 A/C variant.
47 
 
Angiogenesis Regulatory Genes 
Neoplastic growth is dependent on the formation 
of new blood vessels (neovascularization) for oxygen 
and nutrient supply. Cancer cells stimulate angiogen-
esis, a complex multistep process that involves vari-
ous angiogenic factors and matrix-degrading proteo-
lytic  enzymes.
50  Vascular  endothelial  growth  factor 
(VEGF) is one of the most potent angiogenic factors. 
The association  between various  SNPs  of  VEGF  (-
1154AA and -634CG) and PCa has also been investi-
gated.  In  two  independent  studies,
51,52  the  VEGF  -
1154AA genotype proved to be less frequent in PCa 
patients than in the control subjects. In addition, pa-
tients with the -1154A-allele were significantly less 
susceptible  to  high-grade  tumors  when  compared 
with non-carriers. On the contrary, a significantly in-
creased PCa risk was associated with the VEGF-634 
(GC+CC) combined genotype. The VEGF -634C al-
lele was associated with an aggressive phenotype of 
PCa. Together, the VEGF haplotype (-1154A/-634G) 
was negatively associated with risk of PCa risk and 
aggressive  tumors.  Additional  studies  also  reported 
the  association  between  other  SNPs  for  angiogenic 
factors (e.g., various isoforms of nitric oxide synthe-
sis, epidermal growth factor) and PCa risk.
53,54  
 
Vitamin D Pathway-Related Genes 
Several  studies  have  demonstrated  a  chemopre-
ventive role for Vitamin D in PCa. Vitamin D exerts 
its  anti-tumor  effect  by  increasing  apoptotic-cell 
death,  inhibiting  cell  cycle  progression,  interacting 
with the insuline-like growth factors, and decreasing 
the metastatic potential of PCa. The association be-
tween  Vitamin  D  and  PCa  risk  remains  controver-
sial.
55-57  The  anti-proliferative  effects  of  activated 
Vitamin  D  are  thought  to  be  mediated  through  a 
pathway  that  involves  Vitamin  D  Receptors 
(VDRs).
58  It  is  possible  that  VDR  gene  polymor-
phisms could affect the binding of biologically active 
vitamin D and modulate the anti-proliferative effects 
of Vitamin D. Several studies focused on the six pol-
ymorphic loci (Cdx2, FokI, BsmI, ApaI, TaqI, and the 
poly A microsatellite) of the most common VDR var-
iants.  Initial  reports  revealed  an  association  of  the 
TaqI  tt  and  poly  (A)  SS  genotypes  with  decreased 
PCa risk.
59,60 In another study on the Brazilian popu-
lation, there was no association between the Apal and 
Taql polymorphisms between PCa patients and con-
trols.
61 In a population-based study, the frequency of 
the BsmI, FokI, and poly A genotypes were found to be 
similar in PCa patients and control subjects with no 
association between these variants and PCa.
62 Howev-
er, further stratification showed that in men with local-
ized PCa, the BsmI bb genotype was associated with a Prostate cancer genetic and epigenetic 
 
WWW.ircmj.com Vol 13 February 2011  87 
modest increase in risk when compared with the BB 
genotype. 
 
C. Microsatellite Instability in Prostate Cancer 
In general, loss or gain of chromosomes, could be 
studied by Karyotype, comparative genomic hybridi-
zation  (CGH)  or  fluorescent  in  situ  hybridization 
(FISH).  However,  allelic  imbalances  such  as  mi-
crosatellite instability (MSI) and loss of heterozygosi-
ty (LOH) on chromosomes can be further evaluated 
and  located  with  the  help  of  microsatellite  DNA 
markers.  Microsatellites  are  genetically  unstable, 
short,  polymorphic,  tandem  repeat  DNA  segments 
distributed throughout genome. MSI was prominently 
demonstrated  in  hereditary  non-polyposis  colorectal 
cancer  (HNPCC)  and  has  been  associated  with  de-
fects in certain DNA repair genes.
63,64 Conservation 
of genomic stability is at least partially dependent on 
a  specific  class  of  DNA  mismatch  repair  (MMR) 
genes which are responsible for correcting the mis-
incorporated nucleotides caused by either a replica-
tion error or any chemical induction.
65 Structural and 
functional defects of MMR genes lead to the loss of 
MMR  proteins,  down-regulation  of  MMR  enzyme 
activity,  and  a  lower  expression  of  MMR-related 
genes. Collectively these defects are frequently asso-
ciated  with  a  higher  mutation  rate  (100-1000  fold) 
and  tumorigenesis.
66  Microsatellite  analyses  have 
shown frequent allelic losses on the short or long arm 
of different chromosomes (e.g., 1q, 3p, 5q, 6q, 7q, 8p, 
10q, 13q, 16q, 17p, 17q, 18q) in PCa. Studies have 
indicated  that  the  average  allelic  losses  on  these 
chromosomes range from approximately 13% for 17q 
to 36% for 8p in primary tumors and 27% for 17q to 
61% for 13q in metastatic tumors. Overall, the high-
est allelic loss was 42% and 40% at 16q and 8p re-
gions,  respectively.  Since  the  allelic  imbalance  on 
these two loci has also been associated with PCa link-
age studies, it suggests the presence of TSGs. 
 
D. ETS Gene Fusions 
Oncogenic translocations, the abnormal fusion of 
two genes, result in the formation of chimeric protein 
with dysregulated gene expression and a high poten-
tial for transforming abilities. In most cases the in-
volved  genes  are  transcription  factors  that  bind  to 
their specific target DNA sequences, mostly located 
in the promoter regions of genes and increase or de-
crease their expression. The ETS transcription factors 
can change the expression of several proteins which 
are involved in a variety of signaling pathways regu-
lating  cell  growth,  senescence,  apoptosis,  motility, 
and carcinogenesis. Following gene fusion, the ETS 
transcription  factors  abnormally  activate  or  silence 
their specific target genes leading to oncogenic trans-
formation.
67 The discovery of ETS gene fusions has 
improved  our  understanding  of  early  PCa  develop-
ment.  Fusion  of  the  AR-regulated  gene  transmem-
brane protease, serine 2 (TMPRSS2) to the ETS fami-
ly  member,  ERG  (v-ets  erythroblastosis  virus  E26 
oncogene homolog) is observed in approximately half 
of PCa. The TMPRSS2-ERG fusion results in a high 
expression of the ERG gene and is believed to serve 
as  a  driving  force  behind  prostate  tumorigenesis.
68 
Other groups have also identified such translocations 
in a high percentage of PCa patients.
69,70 Additional 
reports support the presence of ETS translocations in 
aggressive  tumors  and  associates  with  high  PCa-
specific  mortality.
69,71,72  The  fusion  events  that  in-
volve ETS family members are likely to be important 
during  early  carcinogenesis  events  and  continue  to 
exist  in  metastatic  and  castration-resistant  PCa.  So 
far,  no  universally  consistent  association  exists  be-
tween  ETS fusions and the  clinical  outcome  of  the 
disease. It appears that in addition to the ERG gene 
status, other factors or variables play major roles for 
poor clinical outcome. Analysis of the TMPRSS2-ERG 
expression  signature  in  PCa  appears  to  involve  β-
estradiol  signaling  and  histone  deacetylation.
73,74  The 
involvement of epigenetic processes in the modulation 
of TMPRSS2-ERG activity remains to be investigated. 
 
F. Epigenetic Changes in Prostate Cancer 
Epigenetic  refers  to  mechanisms  that  allow  the 
stable transmission of cellular traits without a change 
in the DNA sequence or quantity. Overall, epigenetic 
defects reported in cancers include a) reactivation of 
embryonic genes, b) loss of imprinted genes changing 
inactive and active alleles, c) dysregulated expression 
of  micro-RNAs,  d)  increased  gene  recombination, 
and e) transcriptional silencing of TSGs and house-
keeping genes. Epigenetics encompasses several dif-
ferent phenomena, such as DNA methylation, histone 
modifications,  RNA  interference,  and  genomic  im-
printing. Epigenetic processes regulate gene expres-
sion  and  can  change  malignancy-associated  pheno-
types such as growth, migration, invasion, or angio-
genesis.  Epigenetic  events  may  also  play  a  role  in 
benign prostatic hyperplasia (BPH). Epigenetic regu-
latory mechanisms appear very sensitive to external 
stimuli or influences such as diet and oxidative stress.  
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DNA Methylation Status and Prostate Cancer  
DNA  methylation  is  the  addition  of  a  methyl  
(-CH3) group to the 5’-carbon of cytosine, adjacent to 
guanine in CpG sequences, and catalyzed by a series 
of conserved enzymes known as DNA methyltrans-
ferases (MTases). Most CpG islands are unmethylat-
ed in eukaryotic cells. The CpG island methylation 
occurs in about 1% of the genome, which is less than 
the expected statistical fraction (i.e., 6%). Methylcy-
tosine residues are often found in short stretches of 
CpG-rich regions (i.e., CpG islands) that are 0.5-2 kb 
long and in the 5’ region of approximately 60% of 
genes. The CpG dinucleotides, present in the genome, 
are  commonly  clustered  in  groups  or  CpG  islands 
located mostly at or near the promoters (~60%) and 
initial  exons  of  many  genes.  DNA  methylation 
changes can occur as either hypo- or hypermethyla-
tion; however, both forms can lead to genetic instabil-
ity and transcriptional gene silencing and both have 
been  implicated  in  a  variety  of  human  cancers, in-
cluding PCa.
75 The methyl group is supplied by S-
adenosylmethionine (SAM) (Figure 3) which then is 
recycled via a folate- and cobalamin-dependent path-
way. Hypomethylation or loss of methylation can be 
accelerated  by  altering  this  regenerative  process 
through dietary deficiencies of folic acid, Vitamin B12, 
or other substrates. During this process, DNA methyla-
tion acts as a stable tag on the promoter of a gene and 
recruits methyl-binding proteins (MBD) and other pro-
teins, such as histone deacetylases (HDACs) to form 
large-scale heterochromatic structures that silence the 
associated genes. 
Hypomethylation  predisposes  cells  to  chromoso-
mal aberrations, such as chromosomal breaks, trans-
locations, and aneuploidy (Figure 2). Methylated si-
lencing of proto-oncogenes or other cancer promoting 
genes (e.g., H-RAS) could be reversible and lead to 
the  activation  of  such  genes.
76  Traditionally  DNA 
MTases are divided into two categories, de novo en-
zymes  which  are  responsible  for  establishing  new 
methylation patterns and maintenance enzymes which 
essentially  replicate  the  existing  patterns.
77  DNA 
MTase  1  (DNMT1)  is  a  maintenance  enzyme,  and 
DNA  MTase  3a  and  3b  (DNMT3a  and  DNMT3b) 
perform de novo functions. The DNMT1 activity is 
increased up to 3-folds higher in PCa tissues and cell 
lines than in BPH tissues and cell lines.
78 DNMT2 
and DNMT3a are increased in the LnCaP-r (hormone 
refractory PCa) than in the androgen-sensitive parent 
cells  (LNCaP)  which  suggests  that  changes  in  the 
methylation status may be involved in the androgen-
independent  progression  of  PCa.  A  recent  report 
showed that polymorphism in the DNMT3b increased 
the risk of PCa development by 2.8 folds. Table 4 
lists several important genes that are either silenced 
or inactivated by hypermethylation in PCa. Interest-
ingly,  many  of  the  hypermethylated  genes  are  also 
mutated or deleted in PCa.
79-82 
 
Fig. 3: DNA methylation and cancer.  
The clustered CpG site (CpG island) and transcription start site (arrow) of a hypothetical active gene is shown. 
Methylation occurs on 5’-carbon of cytosine adjacent to guanine. DNA-methyl transferase (MTase) methylates the 
CpG island which recruits the methyl binding domain (MBD) and histone deacetylases (HDACs) to the methylated 
DNA and leads to histone deacetylation, condensation of chromatin, loss of transcription factor (TF) binding, and 
silencing of the gene expression in cancer and other premalignant conditions. MTase converts S-adenosylmethionine 
(SAM) to S-adenosylhomocysteine (SAH). A dietary supply of vitamins B12, B6, and folic acid via several steps re-
generate SAH to SAM. 
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Some  reports  have  indicated  that  methylation 
changes may be more important in prostate carcino-
genesis rather than its metastatic progression.
83 Hyper-
methylation  in  the  high  grade  prostatic  intraepithelial 
neoplasia (HPIN) has been found at GSTpi,
84 an im-
portant gene that is involved in the detoxification of 
electrophilic  compounds,  such  as  carcinogens  and 
cytotoxic drugs, by glutathione conjugation. Hyper-
methylation of GSTpi is one of the most frequent epi-
genetic alteration, with a frequency of 70% to 100% 
in clinical PCa specimens.
83,85 Progressive accumula-
tion of methylated alleles from high grade prostatic 
intraepithelial neoplasia to advance PCa occurs in 14-
3-3σ gene, suggesting a role for this epigenetic event in 
prostate carcinogenesis.
79-82,86 (Table 4) In addition to 
these, more than forty other genes have been reported 
as targets of hypermethylation silencing in PCa.
87 
 
Histone Modifications in Prostate Cancer 
Another distinct epigenetic change that is linked to 
DNA  methylation  is  the  modified  state  of  the  sur-
rounding histones in which the DNA is packaged. The 
N-terminal tails of these highly conserved histone pro-
teins could be covalently or reversibly modified by the 
addition  or  removal  of  acetyl,  methyl,  ubiquitin and 
adenosine  diphosphate-ribosyl  groups.  This  unique 
complex modification pattern (histone code) exists in 
balance and functions to regulate transcriptional activi-
ty levels of the genes.
88 The addition of acetyl groups 
to  the  N-terminal  lysines  of  the  histones  creates  an 
open chromatin conformation which leads to a tran-
scriptional  activation  of  the  genes.  Additionally,  
histone hypoacetylation is associated with DNA meth-
ylation. Primarily the addition of acetyl group on his-
tones H2a, H3 and H4 is catalyzed by enzyme histone 
acetyl  transferases  (HATs).  The  HATs  p300,  PCAF, 
and Tip60 up-regulate AR expression or activity which 
leads to androgen-independent signaling of AR.
88,89  
HDACs, which are frequently upregulated in PCa, 
remove  the  acetyl  groups  from  lysines  on  the  his-
tones.
90 The expression levels of HDAC mRNA and 
proteins are increased up to 3-folds in PCa as com-
pared with BPH tissues and cell lines.
91 The highest 
levels of HDAC1 are detected in hormone refractory 
PCa which supports a role for this epigenetic modifi-
cation in androgen-independent PCa.
92 Histone meth-
ylation on a specific location of the histone tail is an-
other type of histone modification. Additionally, the 
expression of histone methyltransferases is changed 
in PCa. EZH2 is a prototypical example of histone 
methyltransferase  that  methylates  lysine  27  on  his-
tone H3.
93 Methylation of this lysine is a marker of 
increased  gene  expression.  Additionally,  EZH2  ex-
pression  is  up-regulated  in  metastatic  hormone-
refractory PCa and its increased expression in prima-
ry cancers predicts biochemical recurrence.
94 
Table 4: Hypermethylated genes in prostate cancer. 
Gene  Chromosome  Role/Function  Hypermethyaltion   Refs  
14-3-3σ  1p36.11  Cell cycle  99%  76 
GSTM1
a  1p13.3  Glutathione-S-
transferase 
58%  98 
RASSF1α
c  3p21.3  Tumor suppressor  Up to 79%  83 
RARβ
d  3p24  Nuclear hormone 
receptor 
66%  76 
APC
j  5q21-q22  Tumor suppressor  100%  79 
ERα
h  6q25.1  Estrogen receptor  95%  80 
MDR1
e  7q21.1  ABC-transporter  Up to 100%  79 
GSTpi
b  11q13  Glutathione-S-
transferase 
Up to 100%  83  
79 
CD44
f  11p13  Cell adhesion  72%  81 
hSPRY2
g  13q31.1  Inhibitor of cell 
growth  
Up to 82%  82 
ERβ
i  14q23.2  Estrogen receptor  up to 100%  80 
E-cadherin  16q22.1  Tumor suppressor  Up to 72%  81 
a GSTM1, Glutathione S-transferase, 
b GSTpi, Glutathione S-transferase P1 (pi), 
c RSSF1α, Ras association do-
main family 1 gene, 
d RARβ, Retinoic acid receptor beta gene, 
e MDR1, multi-drug resistance 1, 
f CD44, cluster 
differentiation 44, 
g hSPRY2, human sprouty homolog 2, 
h ERα, estrogen receptor alpha, 
I ERβ, estrogen receptor 
beta, 
j APC, adenomatous polyposis coli Koochekpour 
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Genomic Imprinting in Prostate Cancer 
Imprinting  is  a  normal  cellular  process  that  is 
based on the maternal or paternal DNA of origin; one 
allele  is  silenced  and  the  other  one  is  expressed. 
There are more than forty known human genes that 
demonstrate genomic imprinting. The IGF2 and p57 
genes are imprinted in many human tissues and it has 
been reported that IGF2 presents with two alleles in 
PCa as compared with the normal single allele im-
printed pattern in BPH.
95 Therefore IGF2 imprinting 
may increase the chance of prostate carcinogenesis. 
Loss of IGF2 imprinting also occurs with the aging of 
the prostate and during senescence in vitro.
96 Inhibitors 
of DNA MTase can reverse the loss of imprinting and 
modulate IGF2 expression. The p57 tumor suppressor 
gene expression is frequently changed in PCa and its 
gene imprinting is regulated by DNA methylation.
97  
 
G. Diagnostic and Prognostic Aspects of Epigenetic 
Alterations in Prostate Cancer 
Epigenetic Diagnostic Markers 
PSA is the best available marker, but it cannot ef-
fectively differentiate between PCa and other benign 
conditions such as BPH and prostatitis. Therefore the 
false positive PSA test can lead to expensive and in-
vasive approaches such as transrectal prostate biopsy. 
Among  other  genetic  alterations,  aberrant  DNA 
methylation  potentially  might  have  the  potential  as 
diagnostic  epigenetic  marker  for  PCa  and  could  be 
tested in tumor tissues and body fluids (e.g., serum, 
urine).  The  methylation  markers  have  several  ad-
vantages when compared with those genetic markers 
based on  sequence  changes  or  variants (e.g.,  muta-
tion, SNPs, etc). The mthylation markers are simple 
in nature; with high sensitivity, these markers can be 
detected,  either  quantitatively  or  qualitatively,  by 
available  well-established  techniques  (e.g.,  PCR). 
Aberrant DNA methylations are more frequent than 
mutations  and  can  be  identified  by  genome  wide 
screening methodologies. The GSTpi gene is a widely 
investigated  tumor  marker  widely.  GSTpi  is  PCa-
specific, hypermethylated, and silenced in more than 
90% of PCa patients.
98 GSTpi methylation is also de-
tected in the proliferative inflammatory atrophy of the 
prostate, which is a known linked to prostate carcino-
genesis.
99 The GSTP1 hypermethylation is reported in 
the serum samples of 72% of PCa patients, 78% of 
patients with locally invasive or advanced PCa, and 
following prostatic massage, in the urine samples of 
68% of patients with early stage disease.
99 In addition 
to GSTPI, the methylation status of RARβ, CD44, E-
cadherin  (ECAD),  RASSF1A,  APC,  and  the 
tazarotene induced gene 1 (T1G1) have been investi-
gated in PCa patients. Other studies have demonstrat-
ed that a combination of methylation markers in body 
fluids  and  tissues,  including  GSTpi  improves  PCa 
diagnosis. It has been reported that a combination of 
the methyaltion analyses of four genes (MGMT, p16, 
ARF, and GSTP1) in the urine could detect 87% of 
PCa  cases  with  100%  specificity.
100  Additional  de-
tailed  investigations  are  needed  to  systematically 
identify methylation markers for routine clinical and 
histopathological diagnosis. 
 
Epigenetic Prognostic Markers 
In  addition  to  the  potential  diagnostic  value, 
GSTpi hypermethylation is detected in 40% of pre-
operative bone marrow aspirates in patients with ad-
vanced PCa and in 90% of PC patients with lymph 
node involvement.
95 Moreover the methylation status 
of CD44, CAV1, T1G1, and CDH1 may also be useful 
in  the  molecular  staging  and  prediction  of  disease 
progression.
101 High grade PCa cases are associated 
with the hypermethylation of several genes, including 
RASSF1A,  GSTP1,  RARβ,  and  CDH13.
102  A  recent 
report discovered that GSTpi hypermethylation was a 
significant  predictor  of  PSA  recurrence  in  PCa  pa-
tients.
95 Multivariate analyses of APC or GSTpi hy-
permethylation in 74 PCa patients significantly pre-
dicted the time needed for disease progression follow-
ing radical prostatectomy. Bastian et al., in a study 
using  matched  tumor  and  normal  tissues  of  53  pa-
tients,  discovered  that  the  combined  hypermethyla-
tion of GSTpi, APC, and PTGS2 gene correlated with 
other clinical or pathological variables (e., pT-stage, 
Gleason score), with 71.1% to 96.2% sensitivity and 
92.9% to 100% specificity.
103 APC and PSTG2 meth-
ylation status appear to have a higher prognostic val-
ue of PCa in several studies completed to date. In ad-
dition  to  these  promising  hypermethyalted  genes, 
global histone modifications may be associated with 
the risk of PCa recurrence.
104 For example; increased 
global  acetylation  and  histone  methylation  on  his-
tones H3 and H4 permit the stratification of patients 
with low grade tumors into different risk groups for 
recurrence.  Interestingly,  these  patterns  of  histone 
modification were predictors of outcome independent 
of stage, preoperative-PSA, and capsular invasion.
105 
The  predictive  value  of  simulataneously  several 
methylation makers have been shown in other stud-
ies.
106 
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H. Therapeutic Targeting of Epigenetic Processes for 
Prostate Cancer Prevention and Treatment 
Unlike irreversible genetic changes such as muta-
tions, epigenetic changes are reversible and could be 
approached  therapeutically.  Theoretically,  reversing 
these changes allows for the reactivation of TSGs or 
silencing  oncogenes.  Most  chromatin  modifying 
drugs have been studied in hematological malignan-
cies.
106 In PCa, several in vitro and in vivo studies 
have used pharmacological agents to reverse epige-
netic processes. Table 5 lists inhibitors of DNA MTa-
se enzymes and HDACs that are used in phase I or II 
clinical trials. Nucleoside analog inhibitors of DNA 
MTase,  such  as  5-Azacytidine  (5-AC)  and  5-aza-
deoxycytidine (decitabine or DAC) have been exten-
sively used in vitro model systems to reverse abnor-
mal hypermethylation and restore the expression of 
silenced genes; however, clinical success was limited 
with these drugs (Table 5).
107-114 In a phase II study, 14 
patients with recurrent metastatic PCa, following com-
plete  androgen  blockade  and  flutamide  withdrawal, 
were  treated  with  decitabine;  only  two  patients  re-
sponded with stable disease and delayed progression 
time.
108    This  report  concluded  that  decitabine  is  a 
well-tolerated  drug  with  modest  clinical  activity 
against hormone-refractory disease. Zebularine is an-
other inhibitor of DNA MTase which is less toxic and 
more  stable  than  5-AC.  Additionally,  zebularine  has 
also antiproliferative activity that will be more effec-
tive in cancer cells than in normal cells.
109-115 The oli-
godeoxynucleotide MG98, is another MTase inhibitor 
which binds with the 3’-UTR region of the DNMT1 
mRNA  and  leads  to  its  degradation  before  transla-
tion.
116 One disadvantage of the MTase inhibitor is that 
the  chromosomal  site  of  demethylation  cannot  be  
controlled.  In  addition,  non-specificity  of  the  hypo-
methylating effects of MTase inhibitors may promote 
cancer  in  some  situations  which  led  investigators  to 
consider other possibilities, such as inhibiting specific 
methyl-binding proteins which recruit histone modify-
ing enzymes to methylated regions.
104,109-111 
Increased HDAC activity in PCa provides another 
therapeutic opportunity. In vitro studies have demon-
strated the pro-apoptotic and anti-anti-angiogenic ef-
fects of HDAC inhibitors (HDACis) such as MS-275, 
suberoylanilide hydroxamic acid (SAHA), and sodi-
um phenylbutyrate (PB) (Table 5).
112-114 SAHA is a 
class  I  HDACi,  which  significantly  suppresses  the 
growth  of  androgen-sensitive  LNCaP  xenografts  in 
nude mice
117 and PB has a pro-apoptotic activity in 
PCa cell lines.
118 Due to the relative tumor selectivity 
and less toxicity, HDAC inhibitors have been used in 
phase I trials in patients with advanced PCa to evalu-
ate dose tolerance and also biomarker-response (Ta-
ble 5). In a small number of patients, partial treatment 
response was observed in terms of tumor regression, 
stable disease, and biomarker response. 
 
Regulation of Epigenetic Processes by Environmental 
and Dietary Factors 
Environmental  and  dietary  factors  also  regulate 
epigenetic processes. Global and gene-specific DNA 
Table 5: Pharmacological agents modifying epigenetic processes in Phase-I and –II clinical trials. 
  Clinical Trial  Tumor Type  Clinical or Biomarker 
Response 
Refs  
 
DNA MTase
a inhibitor         
 5AC
 e  Phase-I  Solid tumors  No response/Decreased DNMT 
activity 
111 
MG98 
 
Phase-I /-II  Solid tumors  Demethylation/ Disease stabili-
zation in 2/23 patients 
112 
DAC
f  Phase-II  HRPCa
d  Disease stabilization in 2/14 pa-
tients 
113 
114 
HDAC
b inhibitors         
PB
g  Phase-I  Prostate cancer 
Solid tumors 
Disease stabilization in solid tu-
mors, PSA rise in 17/19 patients 
115 
SAHA
g  Phase-I  Solid tumors  Tumor regression 
(1 complete , 5 partial response) 
116 
MS-275  Phase-I  Prostate, lymphoma, and 
other solid tumors 
Partial response 
Biomarker response 
117 
a DNA MTase, DNA methyltransferase, 
b HDAC, histone-deacetylase, 
c SAHA, Suberoylanilide hydroxamic acid, 
dHRPCa, hormone-refractory prostate cancer, 
e 5-AC, 5-Aza-cytidine, 
f DAC,5-aza-2’-Deoxycytidine, 
g PB, Sodi-
um phenylbutyrate.  
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methylation could be affected by carcinogenic com-
pounds found in cigarette smoke, alcohol (ethanol), 
and metals such as nickel, cadmium, and zinc. Die-
tary  supplements  can  change  DNA  methylation  by 
regulating the pathways that produce SAM substrate 
(Figure 2 and 3). In vitro and in vivo studies have 
demonstrated that supplemental folate, choline, or me-
thionine can affect DNA methylation.
119 Diet can ab-
normally change the epihaplotype during the life of an 
organism.  Additionally,  dietary  supplement  of  Vita-
mins A, B6, or B12 were shown to decrease PCa devel-
opment potentially by changing the SAM biosynthesis 
pathway or by acting as an antioxidants.
120 Overall die-
tary constituents such as green tea and selenium are 
believed  to  be  chemopreventive  and  function  as  an 
antioxidant  to  prevent  hypomethylation  in  cell  lines, 
and thereby, guard the genome.
121, 122 
 
I. Epigenetic Alterations in Benign Prostatic Hyper-
plasia 
Available  knowledge  on  epigenetic  changes  in 
NPH  is  limited.  To  date,  several  hypermethylated 
genes, including MDR1, RASSF1a and 14-3-3σ, have 
been  identified  in  BPH  when  compared  to  normal 
tissues, which suggests a role for these methylation 
changes in this growth dysfunction (Table 6). Global 
hypermethylation  are  significantly  higher in normal 
prostatic  epithelium  than  in  BPH  tissues.
123  So  far, 
there is no knowledge on chromatin modifying drugs 
in  BPH;  however,  the  expression  of  HDAC1  and 
DNMT1 proteins in PCa is higher than in BPH. So 
far,  it  is  not  clear  whether  histone  acetylation  or 
methylation is associated with the field effect. Inter-
estingly, hypermethylation of GSTpi and RARβ2 was 
discovered  in  a  subset  of  histologically  normal-
looking  stroma  from  radical  prostatectomy  speci-
mens,  supporting  a  role  for  stromal  methylation  in 
PCa progression.
79-81,124,125 
 
J.  Genome-Wide  Association  Studies  (GWAS)  and 
Prostate Cancer 
Interest  in  genome-wide  association  studies 
(GWAS) was initiated with the observations that as-
sociation studies  could  provide  significantly  greater 
power than linkage analyses when detecting genetic 
variants with minor to moderate phenotypic effects.
3 
Although PCa is one of the most heritable cancers, 
identification  of  its  underlying  genetic  causes  has 
proved  difficult.  In  the  last  several  years,  several 
GWA studies have detected a few germline SNPs that 
are individually associated with a relatively moderate 
increase  in  PCa  risk.
26-28,126-130  If  combined,  these 
SNPs might be more informative in detecting higher 
risk among carriers. Moreover, expression array anal-
yses identified many genetic alterations such as so-
matic mutations, chromosomal aberrations, and recur-
rent gene fusions. 
 
K. Conclusions and Future Directions 
The linkage between epigenetic changes and pros-
tate carcinogenesis or progression has led to new in-
sights into PCa phenotypes and many novel molecu-
lar  biomarkers  that  might  change  clinical  diagnosis 
and management. Genetic changes are generally per-
manent  and  irreversible.  Epigenetic  changes  are  an 
early event in carcinogenesis which can be used to 
assess the risk of developing PCa, and specifically, 
are  susceptible  to  changes  resulting  from  environ-
mental stimuli or factors such as diet and life style. 
The identification of epigenetic changes will eventu-
ally help us to understand better the complexity of 
regulatory  pathways  for  gene  expression  in  normal 
and PCa cells. Alterations in DNA methylation occur 
commonly  in  genetically  identical  tumors,  having 
different  phenotypes.  New  techniques,  such  as  ge-
nomic  fingerprinting,  have  the  potential  to  identify 
and  classify  methylation  changes  in  individual  tu-
mors. Chromatin immunoprecipitation (ChIP) micro-
array, so called ChIP-on-a-chip, could identify global 
changes  in  histone  modifications  (e.g.,  acetylation, 
methylation) and the histone code in PCa and BPH. 
High throughput assays such as genome-wide associa-
tion studies (GWAS) will lead to the development of 
PCa  epigenetic  signatures.  Epigenetic  changes  could 
be reversed by using modifiers of epigenetic processes 
such as DNA MTases and HDACs. Since epigenetic 
changes are early events in the PCa development, these 
modifiers (drugs) have the potential to be used in dis-
Table 6: Hypermethylated genes in benign prostatic hyperplasia. 
 
Gene 
 
Chromosome 
 
Role/Function 
 
Hypermethyaltion 
 
Refs 
14-3-3σ  1p36.11  Cell cycle  100%  128 
RASSF1α
a  3p21.3  Tumor suppressor  29%  79 
MDR1
b  7q21.1  ABC-transporter  71%  79 
CD44
c  11p13  Cell adhesion  38%  81 
MT1G
d   16q13  Heavy metal binding  10%  81 
aRSSF1α, Ras association domain family 1 gene; 
bMDR1, multi-drug resistance 1; 
cCD44, cluster differentiation 44; 
dMT1G, metallothionein 1G. 
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ease prevention. Ultimately, rational strategies for dis-
covering efficient combinatorial therapies, using epi-
genetic modifiers along with other drugs, will ultimate-
ly lead to improvements in PCa outcomes. Such tech-
nological  advances  are  likely  to  identify  epigenetic 
changes  in  tumor  specimens  and  assist  urologist-
oncologists in their clinical management of PCa. 
 
Acknowledgment 
 
Due to space limitations, I was unable to discuss and 
cite several other important contributions to the field of 
genetics,  epigenetics,  and  PCa  articles  in  this  review 
article. I am indebted to my former teachers at Shiraz 
Medical School, my mentors at National Cancer Insti-
tute-National  Institute  of  Health,  and  to  the  patients, 
their families, and the physicians for contributing to the 
studies performed in the author’s laboratory. Thanks to 
Miss Jonna Ellis for editorial assistance and to the anon-
ymous referees for their comments on this article. 
 
Conflict of interest: None declared. 
 
References 
 
 
1  Schröder  FH.  Prostate  cancer 
around the world. An overview.  Urol 
Oncol  2010;28:663-7.  [21062647] 
[doi:10.1016/j.urolonc. 2009.12.013] 
2  Jemal  A,  Center  MM,  DeSantis  C, 
Ward EM. Global patterns of cancer 
incidence  and  mortality  rates  and 
trends. Cancer Epidemiol Biomarkers 
Prev.  2010;19:1893-907. 
[20647400]  [doi:10.1158/1055-
9965.EPI-10-0437] 
3  Risch N, Merikangas K. The future 
of  genetic  studies  of  complex  hu-
man  diseases.  Science.  1996;273: 
1516-7.  [8801636]  [doi:10.1126/ 
science.273.5281.1516] 
4  Kruglyak  L.  Prospects  for  whole-
genome  linkage  disequilibrium 
mapping of common disease genes. 
Nat  Genet.  1999;22:139-44.  [1036 
9254] [doi:10.1038/9642] 
5  Collins FS, Brooks LD, Chakravarti 
AA.  DNA  polymorphism  discovery 
resource for research on human ge-
netic variation. Genome Res. 1998; 
8:1229-31. [9872978] 
6  Marks PA, Richon VM, Rifkind RA. 
Histone  deacetylase  inhibitors:  in-
ducers of differentiation or apoptosis 
of transformed cells. J  Natl  Cancer 
Inst.  2000;92:1210-6.  [10922406] 
[doi:10.1093/jnci/92.15.1210] 
7  Gurova KV, Roklin OW, Krivokrysen-
ko  VI,  Chumakov  PM,  Cohen  MB, 
Feinstein E, Gudkov AV. Expression 
of prostate specific antigen (PSA) is 
negatively regulated by p53. Onco-
gene.  2002;21:153-7.  [117  91186] 
[doi:10.1038/sj.onc.1205001] 
8  Li LC, Carroll PR, Dahiya R. Epige-
netic  changes  in  prostate  cancer: 
implication  for  diagnosis  and  treat-
ment.  J  Natl  Cancer  Inst.  2005; 
97:103-15. [15657340] [doi:10.1093/ 
jnci/dji010] 
9  Collins  N,  Poot  RA,  Kukimoto  I, 
Garcia-Jimenez C, Dellaire G, Var-
ga-Weisz PD. An ACF1-ISWI chro-
matin-remodeling complex is requr-
ied for DNA replication through het-
erochromatin.  Nat  Genet.  2002; 
32:627-32.  [12434153]  [doi:10.10 
38/ng1046] 
10  Deuring  R,  Fanti  L,  Armstrong  JA, 
Sarte  M,  Papoulas  O,  Prestel  M, 
Daubresse G, Verardo M, Moseley 
SL, Berloco M, Tsukiyama T, Wu C, 
Pimpinelli S, Tamkun JW. The ISWI 
chromatin-remodeling  protein  is  re-
quired for gene expression and the 
maintenance  of  higher  order  chro-
matin  structure  in  vivo.  Mol  Cell. 
2000;5:355-65.  [10882076]  [doi:10. 
1016/S1097-2765(00)80430-X] 
11  Havas  K,  Whitehouse  I,  Owen-
Hughes T. ATP-dependent chroma-
tin  remodeling  activities.  Cell  Mol 
Life  Sci.  2001;58:673-82. 
[11437229] 
[doi:10.1007/PL00000891] 
12  Veldscholte  J,  Ris-Stalpers  C,  Kui-
per  GG,  Jenster  G,  Berrevoets  C, 
Claassen E, van Rooij HC, Trapman 
J, Brinkmann AO, Mulder E. A muta-
tion in the ligand binding domain of 
the  androgen  receptor  of  human 
LNCaP cells affects steroid binding 
characteristics and response to anti-
androgens.  Biochem  Biophys  Res 
Commun.  1990;173:534-40.  [2260 
966]  [doi:10.1016/S0006-291X(05) 
80067-1] 
13  Gottlieb B, Beitel LK, Wu JH, Trifiro 
M. The androgen receptor gene mu-
tations database (ARDB): 2004 up-
date.  Hum  Mutat.  2004;23:527-33. 
[1  5146455] 
[doi:10.1002/humu.20044] 
14  Bubendorf  M,  Kononen  J,  Koivisto 
P, Schraml P, Moch H, Gasser TC, 
Willi N, Mihatsch MJ, Sauter G and 
Kallioniemi OP. Survey of gene am-
plifications  during  prostate  cancer 
progression  by  high-throughput  fluo-
rescence in situ hybridization on tissue 
microarrays.  Cancer  Res.  1999; 
59:803-6. [10029066] 
15  Linja MJ, Visakorpi T. Alterations of 
androgen  receptor  in  prostate  can-
cer.  J  Steroid  Biochem  Mol  Biol. 
2004;92:255-64. [15663988] [doi:10. 
1016/j.jsbmb.2004.10.012] 
16  Karayi MK, Neal DE, Markham AF. 
Current status of linkage studies in 
hereditary prostate cancer. BJU Int. 
2000;86:659-69. [11069373] [doi:10. 
1046/j.1464-410x.2000.00837.x] 
17  Xu J, Meyers D, Freije D, Isaacs S, 
Wiley  K,  Nusskern  D,  Ewing  C, 
Wilkens E, Bujnovszky P, Bova GS, 
Walsh  P,  Isaacs  W,  Schleutker  J, 
Matikainen M, Tammela T, Visakorpi 
T, Kallioniemi OP, Berry R, Schaid 
D,  French  A,  McDonnell  S, 
Schroeder J, Blute M, Thibodeau S, 
Grönberg H, Emanuelsson M, Dam-
ber JE, Bergh A, Jonsson BA, Smith 
J,  Bailey-Wilson  J,  Carpten  J, 
Stephan D, Gillanders E, Amundson 
I,  Kainu  T,  Freas-Lutz  D,  Baffoe-
Bonnie A, Van Aucken A, Sood R, 
Collins  F,  Brownstein  M,  Trent  J. 
Evidence for a prostate cancer sus-
ceptibility  locus  on  the  X  chromo-
some.  Nat  Genet.  1998;20:175-9. 
[9771711] [doi:10.1038/2477] 
18  Mononen  N,  Syrjäkoski  K,  Mat-
ikainen M, Tammela TL, Schleutker 
J, Kallioniemi OP, Trapman J, Koi-
visto  PA.  Two  percent  of  Finnish 
prostate  cancer  patients  have  a 
germ-line mutation in the hormone-
binding domain of the androgen re-
ceptor  gene.  Cancer  Res.  2000; 
60:6479-81. [11103816] 
19  Gruber  SB,  Chen  H,  Tomsho  LP, 
Lee  N,  Perrone  EE,  Cooney  KA. 
R726L  androgen  receptor  mutation 
is  uncommon  in  prostate  cancer 
families in the United States. Pros-
tate.  2003;54:306-9.  [12539229] 
[doi: 10.1002/pros.10195] 
20  Crocitto  LE,  Henderson  BE,  Coet-
zee  GA.  Identification  of  two 
germline  point  mutations  in  the 
5'UTR  of  the  androgen  receptor Koochekpour 
 
WWW.ircmj.com Vol 13 February y 2011  94 
gene in men with prostate cancer. J 
Uro.l  1997;  158:1599-601. 
[9302181]  [doi:10.  1016/S0022-
5347(01)64287-3] 
21  Evans BA, Harper ME, Daniells CE, 
Watts  CE,  Matenhelia  S,  Green  J, 
Griffiths K. Low incidence of andro-
gen receptor gene mutations in hu-
man  prostatic  tumors  using  single 
strand  conformation  polymorphism 
analysis.  Prostate.  1996;28:162-71. 
[8628719]  [doi:10.1002/(SICI)1097-
0045(199603)28:3<162::AID-PROS 
3>3.0.CO;2-H] 
22  Koochekpour S. Androgen receptor 
signaling and mutations in prostate 
cancer.  Asian  J  Androl. 
2010;12:639-57.  [20711217] 
[doi:10.1038/aja. 2010.89]  
23  D'Antonio  JM,  Vander  Griend  DJ, 
Antony  L,  Ndikuyeze  G,  Dalrymple 
SL, Koochekpour S, Isaacs JT. Loss 
of  androgen  receptor-dependent 
growth suppression by prostate can-
cer  cells  can  occur  independently 
from acquiring oncogenic addiction to 
androgen  receptor  signaling.  PLoS 
One. 2010;8;e11475. [20628607] 
24  Hu SY, Liu T, Liu ZZ, Ledet E, Ve-
lasco-Gonzalez  C,  Mandal  DM, 
Koochekpour  S.  Identification  of  a 
novel  germline  missense  mutation 
of the androgen receptor in African 
American men with familial prostate 
cancer.  Asian  J  Androl. 
2010;12:336-43.  [20173765] 
[doi:10.1038/aja. 2010.5] 
25  Thomas  G,  Jacobs  KB,  Yeager  M, 
Kraft P, Wacholder S, Orr N, Yu K, 
Chatterjee  N,  Welch  R,  Hutchinson 
A,  Crenshaw  A,  Cancel-Tassin  G, 
Staats  BJ,  Wang  Z,  Gonzalez-
Bosquet J, Fang J, Deng X, Berndt 
SI,  Calle  EE,  Feigelson  HS,  Thun 
MJ, Rodriguez C, Albanes D, Virtamo 
J,  Weinstein  S,  Schumacher  FR, 
Giovannucci E, Willett WC, Cussenot 
O,  Valeri  A,  Andriole  GL,  Crawford 
ED,  Tucker  M,  Gerhard  DS,  Frau-
meni  JF  Jr,  Hoover  R,  Hayes  RB, 
Hunter DJ, Chanock SJ. Multiple loci 
identified in a genome-wide associa-
tion  study  of  prostate  cancer.  Nat 
Genet.  2008;40:310-5.  [18264096] 
[doi:10.1038/ng.91] 
26  Eeles  RA,  Kote-Jarai  Z,  Giles GG, 
Olama AA, Guy M, Jugurnauth SK, 
Mulholland  S,  Leongamornlert  DA, 
Edwards SM, Morrison J, Field HI, 
Southey MC, Severi G, Donovan JL, 
Hamdy FC, Dearnaley DP, Muir KR, 
Smith C, Bagnato M, Ardern-Jones 
AT,  Hall  AL,  O'Brien  LT,  Gehr- 
Swain  BN,  Wilkinson  RA,  Cox  A, 
Lewis  S,  Brown  PM,  Jhavar  SG, 
Tymrakiewicz  M,  Lophatananon  A, 
Bryant  SL;  UK  Genetic  Prostate 
Cancer Study Collaborators; British 
Association of Urological Surgeons' 
Section  of  Oncology;  UK  ProtecT 
Study Collaborators, Horwich A, Hud-
dart RA, Khoo VS, Parker CC, Wood-
house CJ, Thompson A, Christmas T, 
Ogden  C,  Fisher  C,  Jamieson  C, 
Cooper CS, English DR, Hopper JL, 
Neal  DE,  Easton  DF.  Multiple  newly 
identified loci associated with prostate 
cancer  susceptibility.  Nat  Genet. 
2008;40:316-21.  [18264097] 
[doi:10.1038/ng.90] 
27  Yeager M, Orr N, Hayes RB, Jacobs 
KB, Kraft P, Wacholder S, Minichiel-
lo MJ, Fearnhead P, Yu K, Chatter-
jee N, Wang Z, Welch R, Staats BJ, 
Calle EE, Feigelson HS, Thun MJ, 
Rodriguez C, Albanes D, Virtamo J, 
Weinstein S, Schumacher FR, Gio-
vannucci  E,  Willett  WC,  Cancel-
Tassin  G,  Cussenot  O,  Valeri  A, 
Andriole  GL,  Gelmann  EP,  Tucker 
M,  Gerhard  DS,  Fraumeni  JF  Jr, 
Hoover R, Hunter DJ, Chanock SJ, 
Thomas  G.  Genome-wide  associa-
tion study of prostate cancer identi-
fies a second risk locus at 8q24. Nat 
Genet.  2007;39:645-9.  [17401363] 
[doi:10. 1038/ng2022] 
28  Gudmundsson  J,  Sulem  P,  Rafnar 
T,  Bergthorsson  JT,  Manolescu  A, 
Gudbjartsson  D,  Agnarsson  BA, 
Sigurdsson  A,  Benediktsdottir  KR, 
Blondal  T,  Jakobsdottir  M,  Stacey 
SN, Kostic J, Kristinsson KT, Birgis-
dottir B, Ghosh S, Magnusdottir DN, 
Thorlacius S, Thorleifsson G, Zheng 
SL,  Sun  J,  Chang  BL,  Elmore  JB, 
Breyer JP, McReynolds KM, Bradley 
KM, Yaspan BL, Wiklund F, Stattin 
P, Lindström S, Adami HO, McDon-
nell  SK,  Schaid  DJ,  Cunningham 
JM, Wang L, Cerhan JR, St Sauver 
JL, Isaacs SD, Wiley KE, Partin AW, 
Walsh PC, Polo S, Ruiz-Echarri M, 
Navarrete  S,  Fuertes  F,  Saez  B, 
Godino J, Weijerman PC, Swinkels 
DW,  Aben  KK,  Witjes  JA,  Suarez 
BK,  Helfand  BT,  Frigge  ML,  Kris-
tjansson  K,  Ober  C,  Jonsson  E, 
Einarsson  GV,  Xu  J,  Gronberg  H, 
Smith  JR,  Thibodeau  SN,  Isaacs 
WB,  Catalona  WJ,  Mayordomo  JI, 
Kiemeney  LA,  Barkardottir  RB, 
Gulcher  JR,  Thorsteinsdottir  U, 
Kong  A,  Stefansson  K.  Common 
sequence  variants  on  2p15  and 
Xp11.22  confer  susceptibility  to 
prostate  cancer.  Nat  Genet.  2008; 
40:281-3.  [18264098]  [doi:10.1038/ 
ng.89] 
29  Shastry  BS.  SNP  alleles  in  human 
disease  and  evolution.  J  Hum 
Genet.  2002;47:561-6.  [12436191] 
[doi:10.1007/s100380200086] 
30  Thomas G, Jacobs KB, Yeager M, 
Kraft P, Wacholder S, Orr N, Yu K, 
Chatterjee N, Welch R, Hutchinson 
A,  Crenshaw  A,  Cancel-Tassin  G, 
Staats  BJ,  Wang  Z,  Gonzalez-
Bosquet J, Fang J, Deng X, Berndt 
SI,  Calle  EE,  Feigelson  HS,  Thun 
MJ, Rodriguez C, Albanes D, Virtamo 
J,  Weinstein  S,  Schumacher  FR, 
Giovannucci E, Willett WC, Cussenot 
O, Valeri A, Andriole GL, Crawford 
ED,  Tucker  M,  Gerhard  DS, 
Fraumeni  JF  Jr,  Hoover  R,  Hayes 
RB, Hunter DJ, Chanock SJ. Multi-
ple loci identified in a genome-wide 
association  study  of  prostate  can-
cer.  Nat  Genet.  2008;40:310-5. 
[18264096] [doi:10.1038/ng.91] 
31  Kote-Jarai  Z,  Easton  DF,  Stanford 
JL, Ostrander EA, Schleutker J, In-
gles  SA,  Schaid  D,  Thibodeau  S, 
Dörk T, Neal D, Donovan J, Hamdy 
F, Cox A, Maier C, Vogel W, Guy M, 
Muir  K,  Lophatananon  A,  Kedda 
MA,  Spurdle  A,  Steginga  S,  John 
EM,  Giles  G,  Hopper  J,  Chappuis 
PO,  Hutter P, Foulkes WD,  Hamel 
N,  Salinas  CA,  Koopmeiners  JS, 
Karyadi  DM,  Johanneson  B, Wahl-
fors T, Tammela TL, Stern MC, Cor-
ral R, McDonnell SK, Schürmann P, 
Meyer A, Kuefer R, Leongamornlert 
DA,  Tymrakiewicz  M,  Liu  JF, 
O'Mara  T,  Gardiner  RA,  Aitken  J, 
Joshi  AD,  Severi  G,  English  DR, 
Southey M, Edwards SM, Al Olama 
AA, PRACTICAL Consortium, Eeles 
RA.  Multiple  novel  prostate  cancer 
predisposition  loci  confirmed  by an 
international study: the PRACTICAL 
Consortium.  Cancer  Epidemiol  Bi-
omarkers  Prev.  2008;17:2052-61. 
[18708398] [doi:10.1158/1055-9965. 
EPI-08-0317] 
32  Zheng SL, Sun J, Wiklund F, Smith 
S, Stattin P, Li G, Adami HO, Hsu 
FC,  Zhu  Y,  Bälter  K,  Kader  AK, 
Turner  AR,  Liu  W,  Bleecker  ER, 
Meyers DA, Duggan D, Carpten JD, 
Chang BL, Isaacs WB, Xu J, Grön-
berg  H.  Cumulative  association  of 
five  genetic  variants  with  prostate 
cancer.  N  Engl  J  Med.  2008;358: 
910-9.  [18199855]  [doi:10.1056/ 
NEJMoa075819] 
33  Rajender S, Singh L, Thangaraj K. 
Phenotypic  heterogeneity  of  muta-
tions  in  androgen  receptor  gene. 
Asian J Androl 2007;9:147-79. [173 
34586]  [doi:10.1111/j.1745-7262. 
2007.00250.x] 
34  Hardy DO, Scher HI, Bogenreider T, 
Sabbatini P, Zhang ZF, Nanus DM, 
Catterall  JF.  Androgen  receptor 
CAG repeat lengths in prostate can-
cer: correlation with age of onset. J 
Clin  Endocrinol  Metab.  1996;81: 
4400-5.  [8954049]  [doi:10.1210/jc. 
81.12.4400] 
35  Jenster G, van der Korput HA, Trap-
man J, Brinkmann AO. Identification 
of two transcription activation units in 
the N-terminal domain of the human 
androgen  receptor.  J  Biol  Chem. 
1995;270:7341-6.  [7706276]  [doi:10. 
1074/jbc.270.13.7341] Prostate cancer genetic and epigenetic 
 
WWW.ircmj.com Vol 13 February 2011  95 
36  Chen  C,  Lamharzi  N,  Weiss  NS, 
Etzioni R, Dightman DA, Barnett M, 
DiTommaso  D,  Goodman  G.    An-
drogen receptor polymorphisms and 
the  incidence  of  prostate  cancer. 
Cancer Epidemiol Biomarkers Prev. 
2002;11:1033-40. [12376504] 
37  Platz EA, Giovannucci E, Dahl DM, 
Krithivas K, Hennekens CH, Brown 
M,  Stampfer  MJ,  Kantoff  PW.  The 
androgen  receptor  gene  GGN  mi-
crosatellite and prostate cancer risk. 
Cancer Epidemiol Biomarkers Prev. 
1988;7:379-84. [9610786] 
38  Lange EM, Sarma AV, Ray A, Wang 
Y,  Ho  LA,  Anderson  SA,  Cunning-
ham JM, Cooney KA. The androgen 
receptor CAG and GGN repeat pol-
ymorphisms  and  prostate  cancer 
susceptibility  in  African-American 
men:  results  from  the  Flint  Men’s 
Health  Study.  J  Hum  Genet. 
2008;53:220-6.  [18217192]  [doi:10. 
1007/s10038-007-0240-4] 
39  Kibel AS, Jin CH, Klim A, Luly J, A 
Roehl K, Wu WS, Suarez BK. Asso-
ciation  between  polymorphisms  in 
cell cycle genes and advanced pros-
tate  carcinoma.  Prostate.  2008;68: 
1179-86.  [18459109]  [doi:10.1002/ 
pros.20784] 
40  Hirata  H,  Kawamoto  K,  Kikuno  N, 
Kawakami T, Kawakami K, Saini S, 
Yamamura  S,  Dahiya  R.  Bcl2-
938C/A  polymorphism  carries  in-
creased  risk  of  biochemical  recur-
rence after radical prostatectomy.  J 
Urol. 2009;181:1907-12. [19237173] 
[doi:10.1016/j.juro.2008.11.093] 
41  Umbas R, Isaacs WB, Bringuier PP, 
Schaafsma  HE,  Karthaus  HF, 
Oosterhof  GO,  Debruyne  FM, 
Schalken JA. Decreased E-cadherin 
expression  is  associated  with  poor 
prognosis  in  patients  with  prostate 
cancer. Cancer Res. 1994;54:3929-
33. [7518346] 
42  Dunsmuir WD, Gillett CE, Meyer LC, 
Young MP, Corbishley C, Eeles RA, 
Kirby  RS.  Molecular  markers  for 
predicting prostate cancer stage and 
survival.  BJU  Int.  2000;86:869-78. 
[11069416]  [doi:10.1046/j.1464-41 
0x.2000.00916.x] 
43  Suzuki  H,  Komiya  A,  Emi  M,  Ku-
ramochi  H,  Shiraishi  T,  Yatani  R, 
Shimazaki  J.  Three  distinct  com-
monly  deleted  regions  of  chromo-
some arm 16q in human primary and 
metastatic  prostate  cancers.  Genes 
Chromosomes  Cancer.  1996; 
17:225-33.  [8946204] 
[doi:10.1002/(SICI)  1098-
2264(199612)17:4<225::AID-
GCC4>3.0.CO;2-5] 
44  Li LC, Chui RM, Sasaki M, Nakajima 
K, Perinchery G, Au HC, Nojima D, 
Carroll  P,  Dahiya  R.  A  single  nu-
cleotide  polymorphism  in  the  E-
cadherin gene promoter alters tran-
scriptional  activities.  Cancer  Res. 
2000;60:873-6. [10706097] 
45  Verhage  BA,  van  Houwelingen  K, 
Ruijter TE, Kiemeney LA, Schalken 
JA. Single-nucleotide polymorphism 
in  the  E-cadherin  gene  promoter 
modifies the risk of prostate cancer. 
Int  J  Cancer.  2002;100:683-5.  [12 
209606] [doi:10.1002/ijc.10541] 
46  Arandi N, Talei A, Erfani N, Ghaderi 
A. Intercellular adhesion molecule-1 
genetic  markers  (+241G/A  and 
+469A/G)  in  Iranian  women  with 
breast cancer. Cancer Genet Cyto-
genet.  2008;183:9-13.  [18474291] 
[doi:10.1016/j.cancergencyto.2008.0
1.019] 
47  Chen H, Hernandez W, Shriver MD, 
Ahaghotu  CA,  Kittles  RA.  ICAM 
gene  cluster  SNPs  and  prostate 
cancer  risk  in  African  Americans. 
Hum  Genet.  2006;120:69-76.  [167 
33712]  [doi:10.1007/s00439-006-
0184-3] 
48  Shirai A, Furukawa M, Yoshizaki T. 
Expression of intercellular adhesion 
molecule (ICAM)-1 in adenoid cystic 
carcinoma  of  the  head  and  neck. 
Laryngoscope.  2003;113:1955-60. 
[14603055]  [doi:10.1097/00005537-
200311000-00019] 
49  Tachimori A, Yamada N, Sakate Y, 
Yashiro M,  Maeda K,  Ohira M, Ni-
shino H, Hirakawa K. Up regulation 
of ICAM-1 gene expression inhibits 
tumour growth and liver metastasis 
in colorectal carcinoma. Eur J Can-
cer.  2005;41:1802-10.  [16051479] 
[doi:10.1016/j.ejca.2005.04.036] 
50  Hanahan D, Folkman J. Patterns and 
emerging  mechanisms  of  the  angio-
genic  switch  during  tumorigenesis. 
Cell 1996;86:353-64. [8756718] 
51  McCarron  SL,  Edwards  S,  Evans 
PR, Gibbs R, Dearnaley DP, Dowe 
A, Southgate  C, Easton  DF,  Eeles 
RA, Howell WM. Influence of cyto-
kine  gene  polymorphisms  on  the 
development  of  prostate  cancer. 
Cancer Res. 2002;62:3369-72. [120 
67976] 
52  Sfar S, Hassen E, Saad H, Mosbah 
F,  Chouchane  L.  Association  of 
VEGF  genetic  polymorphisms  with 
prostate carcinoma risk and clinical 
outcome.  Cytokine.  2006;35:21-8. 
[16908180] [doi:10.1016/j.cyto.2006. 
07.003] 
53  Lee KM, Kang D, Park SK, Berndt 
SI,  Reding  D,  Chatterjee  N, 
Chanock S, Huang WY, Hayes RB. 
Nitric oxide synthase gene polymor-
phisms  and  prostate  cancer  risk. 
Carcinogenesis.  2009;30:621-5. 
[19168583] 
[doi:10.1093/carcin/bgp028] 
54  Teixeira AL, Ribeiro R, Cardoso D, 
Pinto D, Lobo F, Fraga A, Pina F, 
Calais-da-Silva F, Medeiros R. Ge-
netic polymorphism in EGF is asso-
ciated with prostate cancer aggres-
siveness and progression-free inter-
val  in  androgen  blockade-treated 
patients. Clin Cancer Res. 2008;14: 
3367-71.  [18519765]  [doi:10.1158/ 
1078-0432.CCR-07-5119] 
55  Tuohimaa  P,  Tenkanen  L,  Ahonen 
M, Lumme S, Jellum E, Hallmans G, 
Stattin  P,  Harvei  S,  Hakulinen  T, 
Luostarinen T, Dillner J, Lehtinen M, 
Hakama M. Both high and low levels 
of  blood  vitamin  D  are  associated 
with a higher prostate cancer risk: a 
longitudinal,  nested  case-control 
study in the Nordic countries.  Int J 
Cancer.  2004;108:104-8. 
[14618623] [doi:10.1002/ijc.11375] 
56  Ahn  J,  Albanes  D,  Peters  U, 
Schatzkin  A,  Lim  U,  Freedman  M, 
Chatterjee N, Andriole GL, Leitzmann 
MF, Hayes RB.Prostate, Lung, Colo-
rectal, and Ovarian Cancer Screen-
ing  Trial  Project  Team.  Serum  vita-
min  D  concentration  and  prostate 
cancer  risk:  a  nested  case-control 
study.  J  Natl  Cancer  Inst. 
2008;100:796-804.  [18505967] 
[doi:10.1093/jnci/djn152] 
57  Travis RC, Crowe FL, Allen NE, Ap-
pleby PN, Roddam AW, Tjønneland 
A,  Olsen  A,  Linseisen  J,  Kaaks  R, 
Boeing H, Kröger J, Trichopoulou A, 
Dilis  V,  Trichopoulos  D,  Vineis  P, 
Palli D, Tumino R, Sieri S, Bueno-de-
Mesquita  HB,  van  Duijnhoven  FJ, 
Chirlaque  MD,  Barricarte  A,  Larra-
ñaga N, González CA, Argüelles MV, 
Sánchez MJ, Stattin P, Hallmans G, 
Khaw  KT,  Bingham  S,  Rinaldi  S, 
Slimani N, Jenab M, Riboli E, Key 
TJ.  Serum  vitamin  D  and  risk  of 
prostate  cancer  in  a  case-control 
analysis nested within the European 
Prospective  Investigation  into  Can-
cer and Nutrition (EPIC). Am J Epi-
demiol.  2009;169:1223-32. 
[19359375] [doi:10.1093/aje/kwp022] 
58  Berndt SI, Dodson JL, Huang WY, 
Nicodemus KK. A systematic review 
of vitamin D receptor gene polymor-
phisms and prostate cancer risk.  J 
Urol. 2006;175:1613-23. [16600714] 
[doi:10.1016/S0022-5347(05)00958-4] 
59  Taylor  JA,  Hirvonen  A, Watson  M, 
Pittman G, Mohler JL, Bell DA. As-
sociation of prostate cancer with vit-
amin  D  receptor  gene  polymor-
phism.  Cancer  Res.  1996;56:4108-
10. [8797574] 
60  Ingles SA, Ross RK, Yu MC, Irvine 
RA, La Pera G, Haile RW, Coetzee 
GA. Association of prostate cancer 
risk  with  genetic  polymorphisms  in 
vitamin  D  receptor  and  androgen 
receptor.  J  Natl  Cancer  Inst 
1997;89:166-70.  [8998186]  [doi:10. 
1093/jnci/89.2.166] 
61  Maistro S, Snitcovsky I, Sarkis AS, 
da Silva IA, Brentani MM. Vitamin D 
receptor  polymorphisms  and  pros-Koochekpour 
 
WWW.ircmj.com Vol 13 February y 2011  96 
tate cancer risk in Brazilian men. Int 
J  Biol  Markers.  2004;19:245-9. 
[15503828] 
62  Cheteri  MB,  Stanford  JL, 
Friedrichsen DM, Peters MA, Iwasaki 
L,  Langlois  MC,  Feng  Z,  Ostrander 
EA.  Vitamin  D  receptor  gene  poly-
morphisms and prostate cancer risk. 
Prostate.  2004;59:409-18.  [150650 
89] [doi:10.1002/pros.20001] 
63  Bronner  CE,  Baker  SM,  Morrison 
PT,  Warren  G,  Smith  LG,  Lescoe 
MK, Kane M, Earabino C, Lipford J, 
Lindblom  A,  et  al.  Mutation  in  the 
DNA  mismatch  repair  gene  homo-
logue hMLH1 is associated with he-
reditary non-polyposis colon cancer. 
Nature. 1994;368:258-61. [8145827] 
[doi:10.1038/368258a0] 
64  Leach FS, Nicolaides NC, Papado-
poulos N, Liu B, Jen J, Parsons R, 
Peltomaki  P,  Sistonen  P,  Aaltonen 
LA,  Nystrom-Lahti  M,  et  al.  Muta-
tions of a mutS homolog in heredi-
tary nonpolyposis colorectal cancer. 
Cell. 1993;75:1215-25. [8261515] 
65  Modrich P. Mismatch repair, genetic 
stability, and cancer. Science 1994; 
266:1959-60.  [7801122]  [doi:10.11 
26/science.7801122] 
66  Aebi S, Kurdi-Haidar B, Gordon R, 
Cenni B, Zheng H, Fink D, Christen 
RD,  Boland  CR,  Koi  M,  Fishel  R, 
Howell SB. Loss of DNA mismatch 
repair in acquired resistance to cis-
platin.  Cancer  Res.  1996;56:3087-
90. [8674066] 
67  Cooper  CS  (ed.)  Translocations  in 
Solid  Tumors.  1
st  ed.  Austin,  TX, 
Landes Bioscience, 2002. 
68  Tomlins SA, Rhodes DR, Perner S, 
Dhanasekaran  SM,  Mehra  R,  Sun 
XW, Varambally S, Cao X, Tchinda 
J, Kuefer R, Lee C, Montie JE, Shah 
RB,  Pienta  KJ,  Rubin  MA,  Chin-
naiyan  AM.  Recurrent  fusion  of 
TMPRSS2  and  ETS  transcription 
factor  genes  in  prostate  cancer. 
Science.  2005;310:644-8.  [16254 
181] [doi:10.1126/science.1117679] 
69  Mosquera JM, Perner S, Demichelis 
F, Kim R, Hofer MD, Mertz KD, Par-
is  PL,  Simko  J,  Collins  C,  Bismar 
TA,  Chinnaiyan  AM,  Rubin  MA. 
Morphological features of TMPRSS2-
ERG gene fusion prostate cancer. J 
Pathol.  2007;212:91-101.  [173851 
88] [doi:10.1002/path.2154] 
70  Iljin K, Wolf M, Edgren H, Gupta S, 
Kilpinen S, Skotheim RI, Peltola M, 
Smit  F,  Verhaegh  G,  Schalken  J, 
Nees  M,  Kallioniemi  O.  TMPRSS2 
fusions with oncogenic ETS factors in 
prostate  cancer  involve  unbalanced 
genomic  rearrangements  and  are 
associated  with  HDAC1  and  epige-
netic  reprogramming.  Cancer  Res. 
2006;66:10242-6.  [17079440]  [doi:10. 
1158/0008-5472.CAN-06-1986] 
71  Nam  RK,  Sugar  L,  Yang  W,  Sri-
vastava  S,  Klotz  LH,  Yang  LY, 
Stanimirovic  A, Encioiu  E,  Neill  M, 
Loblaw DA,  Trachtenberg J, Narod 
SA,  Seth  A.  Expression  of  the 
TMPRSS2:ERG  fusion  gene  pre-
dicts  cancer  recurrence  after  sur-
gery  for  localised  prostate  cancer. 
Br J Cancer. 2007;97:1690-5. [1797 
1772] [doi:10.1038/sj.bjc.6604054] 
72  Demichelis F, Fall K, Perner S, An-
drén  O,  Schmidt  F,  Setlur  SR, 
Hoshida  Y,  Mosquera JM, Pawitan 
Y,  Lee  C,  Adami  HO,  Mucci  LA, 
Kantoff  PW,  Andersson  SO,  Chin-
naiyan  AM,  Johansson  JE,  Rubin 
MA.  TMPRSS2:  ERG  gene  fusion 
associated with lethal prostate can-
cer in a watchful waiting cohort. On-
cogene.  2007;26:4596-9.  [17 
237811] [doi:10.1038/sj.onc.1210237] 
73  Iljin K, Wolf M, Edgren H, Gupta S, 
Kilpinen S, Skotheim RI, Peltola M, 
Smit  F,  Verhaegh  G,  Schalken  J, 
Nees M, Kallioniemi O. TMPrss2 fu-
sions  with  oncogenic  eTs  factors  in 
prostate  cancer  involve  unbalanced 
genomic  rearrangements  and  are 
associated with HDAC1 and epige-
netic  reprogramming.  Cancer  Res. 
2006;66:10242-6.  [17079440]  [doi: 
10.1158/0008-5472.CAN-06-1986] 
74  Björkman  M,  Iljin  K,  Halonen  P, 
Sara  H,  Kaivanto  E,  Nees  M,  Kal-
lioniemi OP. Defining the molecular 
action of HDAC inhibitors and syn-
ergism with androgen deprivation in 
erG-positive  prostate  cancer.  Int  J 
Cancer. 2008;123:2774-81. [187982 
65] [doi:10.1002/ijc.23885] 
75  Baylin  SB,  Makos  M,  Wu  JJ,  Yen 
RW, de Bustros A, Vertino P, Nelkin 
BD.  Abnormal  patterns  of  DNA 
methylation in human neoplasia: po-
tential consequences for tumor pro-
gression. Cancer Cells 1991;3:383-
90. [1777359] 
76  Jenuwein  T,  Allis  CD.  Translating 
the  histone  code.  Science.  2001; 
293:1074-80. [11498575] [doi:10.11 
26/science.1063127] 
77  Marks PA, Rifkind RA, Richon VM, 
Breslow  R.  Inhibitors  of  histone 
deacetylase are potentially effective 
anticancer agents. Clin Cancer Res 
2001;7:759-60. [11309319] 
78  Xu W, Cho H, Evans RM. Acetyla-
tion  and  methylation  in  nuclear  
receptor  gene  activation.  Met-
hods  Enzymol.  2003;364:205-23. 
[14631847] 
79  Bastian PJ, Ellinger J, Wellmann A, 
Wernert N, Heukamp LC, Müller SC, 
von  Ruecker  A.  Diagnostic  and 
prognostic  information  in  prostate 
cancer with the help of a small set of 
hypermethylated  gene  loci.  Clin 
Cancer  Res  2005;11:4097-106. 
[15930345]  [doi:10.1158/1078-04 
32.CCR-04-1832] 
80  Sasaki M, Tanaka Y, Perinchery G, 
Dharia  A,  Kotcherguina  I,  Fujimoto 
S, Dahiya R. Methylation and inacti-
vation of estrogen, progesterone, and 
androgen receptors in prostate can-
cer.  J  Natl  Cancer  Inst. 
2002;94:384-90. [11880477] 
81  Singal  R,  Ferdinand  L,  Reis  IM, 
Schlesselman  JJ.  Methylation  of 
multiple genes in prostate cancer and 
the relationship with clinicopathologi-
cal features of disease. Oncol Rep. 
2004;12:631-7. [15289848] 
82  McKie AB, Douglas DA, Olijslagers 
S,  Graham  J,  Omar  MM,  Heer  R, 
Gnanapragasam  VJ,  Robson  CN, 
Leung  HY.  Epigenetic  inactivation  of 
the human sprouty2 (hSPRY2) homo-
logue in  prostate cancer.  Oncogene. 
2005;24:2166-74. [15735753] [doi:10. 
1038/sj.onc.1208371] 
83  Jarrard  DF,  Kinoshita  H,  Shi  Y, 
Sandefur  C,  Hoff  D,  Meisner  LF, 
Chang C, Herman JG, Isaacs WB, 
Nassif N. Methylation of the andro-
gen receptor promoter CpG island is 
associated with loss of androgen re-
ceptor expression in prostate cancer 
cells. Cancer Res. 1998;58:5310-4. 
[9850055] 
84  Suzuki  H,  Ito  H.  Role  of  androgen 
receptor in prostate cancer. Asian J 
Androl. 1999;1:81-5. [11250774] 
85  Chlenski A, Nakashiro K, Ketels KV, 
Korovaitseva  GI,  Oyasu  R.  Andro-
gen receptor expression in androgen-
independent  prostate  cancer  cell 
lines.  Prostate.  2001;47:66-75. 
[11304731] [doi:10.1002/pros.1048] 
86  Izbicka E, MacDonald JR, Davidson 
K,  Lawrence  RA,  Gomez  L,  Von 
Hoff  DD.  5,6  Dihydro-5-azacytidine 
(DHAC)  restores  androgen  respon-
siveness  in  androgen-insensitive 
prostate  cancer  cells.  Anticancer 
Res. 1999;19:1285-91. [10368689] 
87  Bastian  PJ,  Yegnasubramanian  S, 
Palapattu GS, Rogers CG, Lin X, De 
Marzo  AM,  NelsonWG.  Molecular 
biomarker  in  prostate  cancer:  the 
role  ofCpGisland  hypermethylation. 
Eur Urol. 2004;46:698-708. [155484 
35] [doi:10.1016/j.eururo.2004.07.022] 
88  Halkidou  K,  Gnanapragasam  VJ, 
Mehta  PB,  Logan  IR,  Brady  ME, 
Cook S, Leung HY, Neal DE, Robson 
CN. Expression of Tip60, an andro-
gen receptor coactivator, and its role 
in prostate cancer development. On-
cogene.  2003;22:2466-77.  [12717 
424] [doi:10.1038/sj.onc.1206342] 
89  Debes  JD,  Schmidt  LJ,  Huang  H, 
Tindall DJ. p300 mediates androgen-
independent  transactivation  of  the 
androgen receptor by interleukin 6. 
Cancer  Res.  2002;62:5632-6.  [12 
384515] 
90  Patra SK, Patra A, Dahiya R. Histone 
deacetylase  and  DNA  methyltrans-
ferase in human prostate cancer. Bi-Prostate cancer genetic and epigenetic 
 
WWW.ircmj.com Vol 13 February 2011  97 
ochem  Biophys  Res  Commun. 
2001;287:705-13.  [11563853]  [doi: 
10.1006/bbrc.2001.5639] 
91  Rosenbaum  E,  Hoque  MO,  Cohen 
Y, Zahurak M, Eisenberger MA, Ep-
stein  JI,  Partin  AW,  Sidransky  D. 
Promoter  hypermethylation  as  an 
independent prognostic factor for re-
lapse in patients with prostate cancer 
following  radical  prostatectomy.  Clin 
Cancer  Res.  2005;11:8321-5.  [163 
22291]  [doi:10.1158/1078-0432.CC 
R-05-1183] 
92  Halkidou  K,  Gaughan  L,  Cook  S, 
Leung  HY,  Neal  DE,  Robson  CN. 
Upregulation  and  nuclear  recruit-
ment of HDAC1 in hormone refrac-
tory  prostate  cancer.  Prostate. 
2004;59:177-89. [15042618] [doi:10. 
1002/pros.20022] 
93  Kirmizis A, Bartley SM, Kuzmichev 
A, Margueron R, Reinberg D, Green 
R, Farnham PJ. Silencing of human 
polycomb target genes is associated 
with methylation of histone H3 Lys 
27.  Genes  Dev.  2004;18:1592-605. 
[1  5231737] 
[doi:10.1101/gad.1200204] 
94  Varambally  S,  Dhanasekaran  SM, 
Zhou M, Barrette TR, Kumar-Sinha 
C, Sanda MG, Ghosh D, Pienta KJ, 
Sewalt  RG,  Otte  AP,  Rubin  MA, 
Chinnaiyan  AM.  The  polycomb 
group  protein  EZH2  is  involved  in 
progression of prostate cancer. Na-
ture.  2002;419:624-9.  [12374981] 
[doi:10.1038/nature01075] 
95  Jarrard DF, Bussemakers MJ, Bova 
GS,  Isaacs  WB.  Regional  loss  of 
imprinting  of the  insulin-like  growth 
factor II gene occurs in human pros-
tate  tissues.  Clin  Cancer  Res. 
1995;1:1471-8. [9815946] 
96  Fu VX, Schwarze SR, Kenowski ML, 
Leblanc S, Svaren J, Jarrard DF. A 
loss  of  insulin-like  growth  factor-2 
imprinting is modulated by CCCTC-
binding  factor  down-regulation  at 
senescence  in  human  epithelial 
cells. J Biol Chem. 2004;279:52218-
26.  [15471867]  [doi:10.1074/jbc. 
M405015200] 
97  Lodygin  D,  Epanchintsev  A, 
Menssen  A,  Diebold  J,  Hermeking 
H. Functional epigenomics identifies 
genes  frequently  silenced  in  pros-
tate  cancer.  Cancer  Res.  2005; 
65:4218-27.  [15899813]  [doi:10.11 
58/0008-5472.CAN-04-4407] 
98  Lee  WH,  Morton  RA,  Epstein  JI, 
Brooks JD, Campbell PA, Bova GS, 
Hsieh WS, Isaacs WB, Nelson WG. 
Cytidine  methylation  of  regulatory 
sequences  near  the  pi-class  gluta-
thione  S-transferase  gene  accom-
panies human prostatic carcinogen-
esis.  Proc  Natl  Acad  Sci  USA 
1994;91:11733-7. [7972132] [doi:10. 
1073/pnas.91.24.11733] 
99  Nakayama M, Bennett CJ, Hicks JL, 
Epstein  JI,  Platz  EA,  Nelson  WG, 
De Marzo AM. Hypermethylation of 
the  human  glutathione  S-
transferase-pi  gene  (GSTP1)  CpG 
island is present in a subset of pro-
liferative  inflammatory  atrophy  le-
sions but not in normal or hyperplas-
tic epithelium of the prostate: a de-
tailed study using laser-capture mi-
crodissection.  Am  J  Pathol. 
2003;163:923-33. [7972132] 
100  Hoque MO, Topaloglu O, Begum S, 
Henrique  R,  Rosenbaum  E,  Van 
Criekinge W, Westra WH, Sidransky 
D.  Quantitative  methylation-specific 
polymerase chain reaction gene pat-
terns  in  urine  sediment  distinguish 
prostate  cancer  patients  from  con-
trol  subjects.  J  Clin  Oncol. 
2005;23:6569-75.  [16170165]  [doi: 
10.1200/JCO.2005.07.009] 
101  Li  LC,  Okino  ST,  Dahiya  R.  DNA 
methylation  in  prostate  cancer.  Bio-
chim  Biophys  Acta.  2004;1704:87-
102. [15363862] 
102  Das PM, Singal R. DNA methylation 
and  cancer.  J  Clin  Oncol.  2004; 
22:4632-42.  [15542813]  [doi:10.12 
00/JCO.2004.07.151] 
103  Bastian PJ, Ellinger J, Wellmann A, 
Wernert N, Heukamp LC, Müller SC, 
von  Ruecker  A.  Diagnostic  and 
prognostic  information  in  prostate 
cancer with the help of a small set of 
hypermethylated  gene  loci.  Clin 
Cancer Res. 2005;11:4097-106. [15 
930345]  [doi:10.1158/1078-0432. 
CCR-04-1832] 
104  Seligson DB, Horvath S, Shi T, Yu 
H,  Tze  S,  Grunstein  M,  Kurdistani 
SK. Global histone modification pat-
terns predict risk of prostate cancer 
recurrence. Nature. 2005;435:1262-
6.  [15988529]  [doi:10.1038/nature 
03672] 
105  Rhodes  DR,  Sanda  MG,  Otte  AP, 
Chinnaiyan  AM,  Rubin  MA.  Multi-
plex  biomarker  approach  for  deter-
mining risk of prostate-specific anti-
gen-defined  recurrence  of  prostate 
cancer.  J  Natl  Cancer  Inst.  2003; 
95:661-8.  [12734317]  [doi:10.1093/ 
jnci/95.9.661] 
106  Bhalla KN. Epigenetic and chromatin 
modifiers as targeted therapy of he-
matologic  malignancies.  J  Clin  On-
col.  2005;23:3971-93.  [15897549] 
[doi: 10.1200/JCO.2005.16.600] 
107  Goffin  J,  Eisenhauer  E.  DNA  me-
thyltransferase inhibitors-state of the 
art. Ann Oncol. 2002;13.:1699-716. 
[12419742]  [doi:10.1093/annonc/ 
mdf314] 
108  Thibault  A,  Figg  WD,  Bergan  RC, 
Lush  RM,  Myers  CE,  Tompkins  A, 
Reed E, Samid D. A phase II study 
of  5-aza-2_deoxycytidine  (decita-
bine) in hormone independent met-
astatic  (D2)  prostate  cancer.  Tu-
mori. 1998;84:87-9. [9619724] 
109  Gudmundsson  J,  Sulem  P, 
Steinthorsdottir  V,  Bergthorsson  JT, 
Thorleifsson G, Manolescu A, Rafnar 
T,  Gudbjartsson  D,  Agnarsson  BA, 
Baker  A,  Sigurdsson  A,  Ben-
ediktsdottir  KR,  Jakobsdottir  M, 
Blondal T, Stacey SN, Helgason  A, 
Gunnarsdottir  S,  Olafsdottir  A,  Kris-
tinsson KT, Birgisdottir B, Ghosh S, 
Thorlacius  S,  Magnusdottir  D,  Stef-
ansdottir  G,  Kristjansson  K,  Bagger 
Y,  Wilensky  RL,  Reilly  MP,  Morris 
AD, Kimber CH, Adeyemo A, Chen 
Y, Zhou J, So WY, Tong PC, Ng MC, 
Hansen  T,  Andersen  G,  Borch-
Johnsen  K,  Jorgensen  T,  Tres  A, 
Fuertes  F,  Ruiz-Echarri  M,  Asin  L, 
Saez  B,  van  Boven  E,  Klaver  S, 
Swinkels  DW,  Aben  KK,  Graif  T, 
Cashy  J,  Suarez  BK,  van  Vierssen 
Trip  O,  Frigge  ML,  Ober  C,  Hofker 
MH,  Wijmenga  C,  Christiansen  C, 
Rader  DJ,  Palmer  CN,  Rotimi  C, 
Chan  JC,  Pedersen  O,  Sigurdsson 
G,  Benediktsson  R,  Jonsson  E, 
Einarsson GV, Mayordomo JI, Cata-
lona WJ, Kiemeney LA, Barkardottir 
RB,  Gulcher  JR,  Thorsteinsdottir  U, 
Kong A, Stefansson K. Two variants 
on  chromosome  17  confer  prostate 
cancer risk, and the one in TCF2 pro-
tects  against  type  2  diabetes.  Nat 
Genet.  2007;39:977-83.  [17603485] 
[doi:10.1038/ng2062] 
110  Davis  AJ,  Gelmon  KA,  Siu  LL, 
Moore  MJ,  Britten  CD,  Mistry  N, 
Klamut H, D'Aloisio S, MacLean M, 
Wainman  N,  Ayers  D,  Firby  P, 
Besterman JM, Reid GK, Eisenhauer 
EA.  Phase  I  and  pharmacologic 
study  of  the  human  DNA  methyl-
transferase  antisense  oligodeox-
ynucleotide  MG98  given  as  a  21-
day  continuous  infusion  every  4 
weeks.  Invest  New  Drugs.  2003; 
21:85-97.  [12795533]  [doi:10.1023/ 
A:1022976528441] 
111  Hu JF, Nguyen PH, Pham NV, Vu 
TH and Hoffman AR. Modulation of 
Igf2 genomic imprinting in mice  in-
duced  by  5-azacytidine,  an  inhibitor 
of DNA methylation. Mol Endocrinol. 
1997;11:1891-8.  [9415394]  [doi:10. 
1210/me.11.13.1891] 
112  Carducci MA, Gilbert J, Bowling MK, 
Noe D, Eisenberger MA, Sinibaldi V, 
Zabelina Y, Chen TL, Grochow LB, 
Donehower  RC.  A  phase  I  clinical 
and  pharmacological  evaluation  of 
sodium phenylbutyrate on an 120-h 
infusion schedule. Clin Cancer Res. 
2001;7:3047-55. [11595694] 
113  Kelly WK, O'Connor OA,  Krug LM, 
Chiao  JH,  Heaney  M,  Curley  T, 
MacGregore-Cortelli  B,  Tong  W, 
Secrist JP, Schwartz L, Richardson 
S, Chu E, Olgac S, Marks PA, Scher 
H, Richon VM. Phase I study of an Koochekpour 
 
WWW.ircmj.com Vol 13 February y 2011  98 
oral  histone  deacetylase  inhibitor, 
suberoylanilide  hydroxamic  acid,  in 
patients  with  advanced  cancer.  J 
Clin Oncol. 2005;23:3923-31. [1589 
7550] 
[doi:10.1200/JCO.2005.14.167] 
114  Wang XF, Qian DZ, Ren M, Kato Y, 
Wei Y, Zhang L, Fansler Z, Clark D, 
Nakanishi  O,  Pili  R.  Epigenetic 
modulation of retinoic acid receptor 
beta2  by  the  histone  deacetylase 
inhibitor MS-275 in human renal cell 
carcinoma. Clin Cancer Res. 2005; 
11:3535-42.  [15867257]  [doi:10.11 
58/1078-0432.CCR-04-1092] 
115  Cheng  JC,  Yoo  CB,  Weisenberger 
DJ, Chuang J, Wozniak C, Liang G, 
Marquez  VE,  Greer  S,  Orntoft  TF, 
Thykjaer  T,  Jones  PA.  Preferential 
response of cancer cells to zebular-
ine.  Cancer  Cell.  2004;6:151-8. 
[15324698]  [doi:10.1016/j.ccr.2004. 
06.023] 
116  Goffin  J,  Eisenhauer  E.  DNA  me-
thyltransferase inhibitors-state of the 
art.  Ann  Oncol.  2002;13:1699-716. 
[12419742]  [doi:10.1093/annonc/ 
mdf314] 
117  Butler LM, Agus DB, Scher HI, Hig-
gins  B,  Rose  A,  Cordon-Cardo  C, 
Thaler  HT,  Rifkind  RA,  Marks  PA, 
Richon VM. Suberoylanilide hydrox-
amic  acid,  an  inhibitor  of  histone 
deacetylase, suppresses the growth 
of prostate cancer cells in vitro and 
in vivo. Cancer Res. 2000;60:5165-
70. [11016644] 
118  Carducci  MA,  Nelson  JB,  Chan-
Tack KM, Ayyagari SR, Sweatt WH, 
Campbell PA,  Nelson WG, Simons 
JW.  Phenylbutyrate  induces  apop-
tosis in human prostate cancer and 
is more potent than phenylacetate. 
Clin  Cancer  Res.  1996;2:379-87. 
[9816181] 
119  Mikol  YB,  Hoover  KL,  Creasia  D, 
Poirier LA. Hepatocarcinogenesis in 
rats fed methyl-deficient, amino ac-
id-defined  diets.  Carcinogenesis. 
1983;4:1619-29.  [6317218]  [doi:10. 
1093/carcin/4.12.1619] 
120  Harnack L, Jacobs DR Jr., Nicode-
mus  K,  Lazovich  D,  AndersonK, 
Folsom  AR.  Relationship  of  folate, 
vitamin B-6, vitamin B-12, and me-
thionine intake to incidence of colo-
rectal  cancers.  Nutr  Cancer. 
2002;43:152-8.  [12588695]  [doi:10. 
1207/S15327914NC432_5] 
121  Lyn-Cook  BD,  Rogers  T,  Yan  Y, 
Blann  EB,  Kadlubar FF,  Hammons 
GJ. Chemopreventive effects of tea 
extracts and various components on 
human  pancreatic  and  prostate  tu-
mor  cells  in  vitro.  Nutr  Cancer 
1999;35:80-6.  [10624710]  [doi:10. 
1207/S1532791480-86] 
122  Davis  CD,  Uthus  EO,  Finley  JW. 
Dietary selenium and arsenic affect 
DNA methylation in vitro in Caco-2 
cells and in vivo in rat liver and co-
lon.  J  Nutr.  2000;130:2903-9.  [11 
110844] 
123  Bedford MT, van Helden PD. Hypo-
methylation  of  DNA  in  pathological 
conditions  of  the  human  prostate. 
Cancer  Res.  1987;47:5274-6. 
[2443238] 
124  Hanson JA, Gillespie JW, Grover A, 
Tangrea MA, Chuaqui RF, Emmert-
Buck  MR,  Tangrea  JA,  Libutti  SK, 
Linehan  WM,  Woodson  KG.  Gene 
promoter  methylation  in  prostate 
tumor-associated  stromal  cells.  J 
Natl  Cancer  Inst.  2006;98:255-61. 
[16478744] [doi:10.1093/jnci/djj051] 
125  Henrique  R,  Jerónimo  C,  Hoque 
MO, Carvalho AL, Oliveira J, Teixei-
ra MR, Lopes C, Sidransky D. Fre-
quent 14-3-3 sigma promoter meth-
ylation  in  benign  and  malignant 
prostate  lesions.  DNA  Cell  Biol. 
2005;24:264-9.  [15812243]  [doi:10. 
1089/dna.2005.24.264] 
126  Witte  JS.  Multiple  prostate  cancer 
risk  variants  on  8q24.  Nat  Genet. 
2007;39:579-80. [17460686] [doi:10. 
1038/ng0507-579] 
127  Gudmundsson J, Sulem P, Manoles-
cu A, Amundadottir LT, Gudbjartsson 
D, Helgason A, Rafnar T, Bergthors-
son JT, Agnarsson BA, Baker A, Sig-
urdsson A, Benediktsdottir KR, Jak-
obsdottir M, Xu J, Blondal T, Kostic J, 
Sun J, Ghosh S, Stacey SN, Mouy 
M, Saemundsdottir J, Backman VM, 
Kristjansson  K,  Tres  A,  Partin  AW, 
Albers-Akkers MT, Godino-Ivan Mar-
cos J, Walsh PC, Swinkels DW, Na-
varrete S, Isaacs SD, Aben KK, Graif 
T,  Cashy  J,  Ruiz-Echarri  M,  Wiley 
KE, Suarez BK, Witjes JA, Frigge M, 
Ober  C,  Jonsson  E, Einarsson  GV, 
Mayordomo JI, Kiemeney LA, Isaacs 
WB,  Catalona  WJ,  Barkardottir  RB, 
Gulcher JR, Thorsteinsdottir U, Kong 
A,  Stefansson  K.  Genome-wide  as-
sociation  study  identifies  a  second 
prostate cancer susceptibility variant 
at 8q24.  Nat Genet. 2007;39:631-7. 
[1740  1366]  [doi:10.1038/ng1999] 
Haiman CA, Patterson N, Freedman 
ML,  Myers  SR,  Pike  MC,  Wal-
iszewska A, Neubauer J, Tandon A, 
Schirmer  C,  McDonald  GJ,  Green-
way SC, Stram DO, Le Marchand L, 
Kolonel  LN,  Frasco  M,  Wong  D, 
Pooler LC, Ardlie K, Oakley-Girvan 
I, Whittemore AS, Cooney KA, John 
EM, Ingles SA, Altshuler D, Hender-
son  BE,  Reich  D.  Multiple  regions 
within 8q24 independently affect risk 
for  prostate  cancer.  Nat  Genet. 
2007;39:638-44. [17401364] [doi:10. 
1038/ng2015] 
128  Gudmundsson  J,  Sulem  P, 
Steinthorsdottir V, Bergthorsson JT, 
Thorleifsson  G,  Manolescu  A,  Raf-
nar  T,  Gudbjartsson  D,  Agnarsson 
BA,  Baker  A,  Sigurdsson  A,  Ben-
ediktsdottir  KR,  Jakobsdottir  M, 
Blondal T, Stacey SN, Helgason A, 
Gunnarsdottir S, Olafsdottir A, Kris-
tinsson KT, Birgisdottir B, Ghosh S, 
Thorlacius S, Magnusdottir D, Stef-
ansdottir G, Kristjansson K, Bagger 
Y,  Wilensky  RL,  Reilly  MP,  Morris 
AD, Kimber CH, Adeyemo A, Chen 
Y,  Zhou  J,  So  WY,  Tong  PC,  Ng 
MC, Hansen T, Andersen G, Borch-
Johnsen  K,  Jorgensen  T,  Tres  A, 
Fuertes  F,  Ruiz-Echarri  M,  Asin L, 
Saez  B,  van  Boven  E,  Klaver  S, 
Swinkels  DW,  Aben  KK,  Graif  T, 
Cashy J, Suarez BK, van Vierssen 
Trip O, Frigge ML, Ober C, Hofker 
MH,  Wijmenga  C,  Christiansen  C, 
Rader  DJ,  Palmer  CN,  Rotimi  C, 
Chan  JC,  Pedersen  O,  Sigurdsson 
G,  Benediktsson  R,  Jonsson  E, 
Einarsson GV, Mayordomo JI, Cata-
lona WJ, Kiemeney LA, Barkardottir 
RB, Gulcher JR, Thorsteinsdottir U, 
Kong A, Stefansson K. Two variants 
on chromosome 17 confer prostate 
cancer  risk,  and  the  one  in  TCF2 
protects  against  type  2  diabetes. 
Nat  Genet.  2007;39:977-83.  [1760 
3485] [doi:10.1038/ng2062] 
129  Duggan D, Zheng SL, Knowlton M, 
Benitez  D,  Dimitrov  L,  Wiklund  F, 
Robbins C, Isaacs SD, Cheng Y, Li 
G,  Sun  J,  Chang  BL,  Marovich  L, 
Wiley KE, Bälter K, Stattin P, Adami 
HO, Gielzak M, Yan G, Sauvageot 
J,  Liu  W,  Kim  JW,  Bleecker  ER, 
Meyers  DA,  Trock  BJ,  Partin  AW, 
Walsh PC, Isaacs WB, Grönberg H, 
Xu  J,  Carpten  JD.  Two  genome-
wide association studies of aggres-
sive prostate cancer implicate puta-
tive prostate tumor suppressor gene 
DAB2IP. J Natl Cancer Inst. 2007; 
99:1836-44.  [18073375]  [doi:10.10 
93/jnci/djm250] 
130  Duggan D, Zheng SL, Knowlton M, 
Benitez  D,  Dimitrov  L,  Wiklund  F, 
Robbins C, Isaacs SD, Cheng Y, Li 
G,  Sun  J,  Chang  BL,  Marovich  L, 
Wiley KE, Bälter K, Stattin P, Adami 
HO, Gielzak M, Yan G, Sauvageot 
J,  Liu  W,  Kim  JW,  Bleecker  ER, 
Meyers  DA,  Trock  BJ,  Partin  AW, 
Walsh PC, Isaacs WB, Grönberg H, 
Xu  J,  Carpten  JD.  Two  genome-
wide association studies of aggres-
sive prostate cancer implicate puta-
tive prostate tumor suppressor gene 
DAB2IP.  J  Natl  Cancer  Inst. 
2007;99:1836–44.  doi:  10.10 
93/jnci/djm250
 